

PCT



WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/44, C07D 401/12, 213/74, 413/12		A1	(11) International Publication Number: WO 98/58646
			(43) International Publication Date: 30 December 1998 (30.12.98)
(21) International Application Number: PCT/DK98/00267		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 22 June 1998 (22.06.98)			
(30) Priority Data: 0747/97 24 June 1997 (24.06.97) DK 60/051,300 30 June 1997 (30.06.97) US			
(71) Applicant: NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsvaerd (DK).			
(72) Inventors: ANKERSEN, Michael; l.th. Dalgashave 34, DK-2000 Frederiksberg (DK). STIDSEN, Carsten, Enggaard; Christopher Boecks Allé 109, DK-2860 Søborg (DK). CRIDER, Michael, Albert; 307 Lakewood Drive, Monroe, LA 71203 (US).		Published With international search report.	

(54) Title: USE OF SOMATOSTATIN AGONISTS AND ANTAGONISTS FOR TREATING DISEASES RELATED TO THE EYE



(57) Abstract

The invention relates to the use of a somatostatin receptor ligand of nonpeptide origin, e.g. of general formula (1a) or (1b) or a pharmaceutically acceptable salt thereof, which has high and/or selective affinity to the somatostatin receptor protein designated SSTR4, for the preparation of a medicament for the treatment of a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal. Such conditions being high intraocular pressure (IOP) and/or deep ocular infections. The diseases which may be treated are e.g. glaucoma, stromal keratitis, iritis, retinitis, cataract and conjunctivitis.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

USE OF SOMATOSTATIN AGONISTS AND ANTAGONISTS FOR TREATING DISEASES RELATED TO THE EYE

5 FIELD OF INVENTION

The present invention relates to use of a compound for the preparation of a composition for treating medical disorders related to binding to human somatostatin receptor subtypes, in particular SSTR4.

10

BACKGROUND OF THE INVENTION

Somatostatin (somatotropin release inhibiting factor; SRIF), a tetradecapeptide originally isolated from ovine hypothalamus on the basis of its ability to inhibit growth hormone release from anterior pituitary cells (Brazeau, P. et al., *Science* **179**, 77-79, 1973) has been shown to be present in several other tissues (for a review see Reichlin, S., *N. Engl. J. Med.* **309**, 1495-1501, 1983 and *ibid*, 1556-1563). Somatostatin appears to have widespread functions as a modulator of neuronal activity as well as of endocrine and exocrine secretion. Inhibitory effects of this peptide on the release of a variety of hormones such as growth hormone, prolactin, glucagon, insulin, gastrin and thyroid stimulating hormones have been described (for a review see Wass, J.A.H., in *Endocrinology*, ed. deGrott, L.J., vol 1, 152-166, 1989). Somatostatin is best regarded as belonging to a phylogenetically ancient, multigene family of peptides with two important bioactive products, namely SRIF-14 (SRIF) and SRIF-28, a congener of SRIF extended at the N-terminus.

The regulatory functions of SRIF are mediated by specific membrane receptors. Currently, only agonists are available to study the pharmacology of SRIF receptors.

High-affinity saturable binding sites have been demonstrated in a number of tissues, e.g. pituitary gland, brain and pancreas. Within the last few years the cloning and

isolation of five somatostatin receptor genes has been reported for various species (human, rat, mouse and bovine). Structural analysis of the encoded proteins revealed that the somatostatin receptor proteins (SST1-SST5) represent a distinct receptor subfamily (named the A5 subfamily) belonging to the superfamily of G protein-coupled receptors with seven putative membrane spanning regions.

Recent work on the development of nonpeptide structures substituting the peptide backbone of small cyclic peptides with a β -D-glucose scaffold (Hirschmann, R. *et al.*, J.Am. Chem.Soc. **115**, 12550-12568, 1993) or xylofuranose scaffold (Papageorgiou, C. *et al.*, Bioorg.Med.Chem.Lett. **2**, 135-140, 1992) or a benzodiazepinone scaffold (Papageorgiou, C. & Borer, X., Bioorg.Med.Chem.Lett. **6**, 267-272, 1996) demonstrated low somatostatin receptor affinity. However, these structures are nonselective displaying higher affinities for both β 2-adrenergic receptors and tachykinin receptors.

The distribution of somatostatin receptors (SSTR1-5) has been investigated by Mori et al. and is disclosed in Neuroscience Letters 223 (1997) 185-188. They have determined that SSTR4 and SSTR2 are expressed predominantly in the eye of a rat, more particularly in the iris-ciliary body and retina. Moreover in situ hybridization showed predominant SSTR4 expression in the posterior iris epithelium and ciliary body. Mori et al. states that somatostatin lowers intraocular pressure (IOP), and that ligands for SSTR4 may be expected as anti-glaucoma drugs.

Thus, there have been no reports in the literature on the successful development of a somatostatin receptor ligand of nonpeptide origin having high affinity and/or selectivity to the somatostatin receptor protein(s) designated SSTR4 and/or SSTR2.

SUMMARY OF THE INVENTION

The present invention relates to the use of a somatostatin receptor ligand of nonpeptide origin, or a pharmaceutically acceptable salt thereof, which has high and/or selective affinity to the somatostatin receptor protein designated SSTR4, for the prepa-

ration of a medicament for the treatment of a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal. Such conditions being high intraocular pressure (IOP) and/or deep ocular infections. The diseases which may be treated are e.g. glaucoma, stromal keratitis, iritis, retinitis, cataract and conjunctivitis.

DETAILED DESCRIPTION OF THE INVENTION

Accordingly, in a first aspect, the present invention relates to the use of a somatostatin receptor ligand of nonpeptide origin, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament, for the treatment of a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal.

In a second aspect the invention relates to the use of a somatostatin receptor ligand of nonpeptide origin, or a pharmaceutically acceptable salt thereof, which has high affinity to the somatostatin receptor protein designated SSTR4, for the preparation of a medicament for the treatment of a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal.

In a third aspect the invention relates to the use of a somatostatin receptor ligand of nonpeptide origin, or a pharmaceutically acceptable salt thereof, which has high and selective affinity to the somatostatin receptor protein designated SSTR4, for the preparation of a medicament for the treatment of a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal.

In a fourth aspect the invention relates to the use of a somatostatin receptor ligand of nonpeptide origin, or a pharmaceutically acceptable salt thereof, which selectively binds to the somatostatin receptor protein designated SSTR4, for the preparation of a medicament for the treatment of a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal.

In a fifth aspect the invention relates to a method of treating a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal, comprising administering to said mammal in need thereof an effective amount of a somatostatin receptor ligand of nonpeptide origin or a pharmaceutically acceptable salt thereof.

In a sixth aspect the invention relates to a method of treating a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal, comprising administering to said mammal in need thereof an effective amount of a somatostatin receptor ligand of nonpeptide origin or a pharmaceutically acceptable salt thereof, which has high affinity to the somatostatin receptor protein designated SSTR4.

In a seventh aspect the invention relates to a method of treating a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal, comprising administering to said mammal in need thereof an effective amount of a somatostatin receptor ligand of nonpeptide origin or a pharmaceutically acceptable salt thereof, which has high and selective affinity to the somatostatin receptor protein designated SSTR4.

In an eighth aspect the invention relates to a method of treating a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal, comprising administering to said mammal in need thereof an effective amount of a somatostatin receptor ligand of nonpeptide origin or a pharmaceutically acceptable salt thereof, which selectively binds to the somatostatin receptor protein designated SSTR4.

Throughout this specification mammal is intended to include rats, pigs, dogs as well as humans.

Throughout this specification a method of treating a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal is also intended to comprise prophylactic treatment.


In one embodiment of the present invention the disease is related to a high intraocular pressure (IOP), such as glaucoma.

- 5 In another embodiment of the present invention the disease is related to deep ocular infections, such as stromal keratitis, iritis or retinitis.


In a further embodiment of the present invention the disease is cataract.

- 10 In a still further embodiment of the present invention the disease is conjunctivitis.

In a particular embodiment of any one of the above first to eighth aspect the somato-statin receptor ligand of nonpeptide origin has the general formula Ia or Ib



or



wherein

- 20 m is 2, 3, 4, 5 or 6,
 n is 1, 2 or 3,
 p is 1, 2, 3, 4, 5 or 6,

R¹ and R² are independently hydrogen or C₁₋₆-alkyl optionally substituted with halogen, amino, hydroxy, alkoxy or aryl,

X is =S, =O, =NH, =NCOPh or =N(CN),

A is aryl optionally substituted with halogen, amino, hydroxy, nitro, C₁₋₆-alkyl, C₁₋₆-alkoxy or aryl,

B is aryl optionally substituted with halogen, amino, hydroxy, C₁₋₆-alkyl, C₁₋₆-alkoxy or aryl,

D is aryl, amino, optionally substituted with halogen, amino, hydroxy, C₁₋₆-alkyl, C₁₋₆-alkoxy or aryl,

or a pharmaceutically acceptable salt thereof.

The compounds of formula Ia or Ib comprise any optical isomers thereof, in the form of separated, pure or partially purified optical isomers or racemic mixtures thereof.

In one embodiment of the compound of formula Ia, X is =S, =NH, =NCOPh, or =N-CN, preferably =S, =NH or =NCOPh.

In another embodiment of the compound of formula Ia or Ib, A is pyridinyl, e.g. pyridin-2-yl, pyridin-3-yl, quinolinyl, e.g. quinol-2-yl, isoquinolinyl, pyrimidinyl, e.g.

pyrimidin-2-yl, pyrazinyl, pyridazinyl, e.g. pyridazin-2-yl, or triazinyl optionally substituted with one halogen, e.g. 5-bromo, amino, hydroxy, nitro, e.g. 5-nitro, C₁₋₆-alkyl, C₁₋₆-alkoxy or aryl.

Preferably A is pyridinyl or quinolinyl optionally substituted with halogen, amino, hydroxy, nitro, C₁₋₆-alkyl, C₁₋₆-alkoxy or aryl, preferably pyridinyl, pyridinyl substituted with bromo or nitro, or quinolinyl.

In a further embodiment of the compound of formula Ia or Ib, B is phenyl, naphthyl, e.g. naphth-1-yl or naphth-2-yl, quinolinyl, isoquinolinyl, indolyl, thienyl, furanyl or

pyridinyl optionally substituted with one or two halogen, e.g. 4-bromo or 3,4-dichloro, amino, hydroxy, C₁₋₆-alkyl, C₁₋₆-alkoxy or aryl.

Preferably B is phenyl or naphthyl optionally substituted with halogen, amino, hydroxy, nitro, C₁₋₆-alkyl, C₁₋₆-alkoxy or aryl, preferably phenyl substituted with bromo or two chloro, or naphthyl, e.g. naphth-1-yl.

In a still further embodiment of the compound of formula Ia or Ib, D is amino, imidazolyl, e.g. 1H-imidazol-4-yl or imidazol-1-yl pyridinyl, e.g. pyridin-2-yl, pyrimidinyl, piperidinyl, pyrrolidinyl, e.g. pyrrolidin-1-yl, piperazinyl, pyridinylamino, pyrimidinylamino, piperidinylamino, pyrrolidinylamino, piperazinylamino, morpholinyl, e.g. morpholin-4-yl, triazolyl, tetrazolyl, thiadiazolyl, isoxazolyl or oxadiazolyl optionally substituted with one or two halogen, amino, hydroxy, C₁₋₆-alkyl, C₁₋₆-alkoxy or aryl.

Preferably D is imidazolyl, morpholinyl, pyrrolidinyl, amino or pyridinylamino optionally substituted with one or two halogen, amino, hydroxy, C₁₋₆-alkyl, C₁₋₆-alkoxy or aryl, preferably imidazolyl, morpholinyl, dimethylamino, pyrrolidinyl, pyridinylamino, amino or pyridinyl.


In a further embodiment of the compound of formula Ia or Ib, R₁ and R₂ are independently of each other hydrogen or C₁₋₆-alkyl, preferably hydrogen or methyl.

Whenever a heteroaryl or aryl is substituted such substitution(s) may be in any possible ring position, which may be recognized by the skilled person without any undue burden.

In a specific embodiment of any one of the above first to eighth aspect the somatostatin receptor ligand of nonpeptide origin is selected from the group consisting of


8

1-(3-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)propyl)-3-(3-(1H-imidazol-4-yl)propyl)thiourea



5


1-(3-(N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino)propyl)-3-(3-(1H-imidazol-4-yl)propyl)thiourea




10

15 1-(4-Aminobutyl)-3-(3-(N-(5-bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)propyl)thiourea

9




1-(3-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)- amino)propyl)-3-(3-(N-(pyridin-
5 2-yl)amino)propyl)thiourea




10


1-(3-(N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino)propyl)-3-(3-(N,N-
15 dimethylamino)propyl)thiourea



1-(3-(N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino)propyl)-3-(3-(morpholin-4-yl)propyl)thiourea




10 1-(3-(N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino)propyl)-3-(3-(imidazol-1-yl)propyl)thiourea



15


20 1-(4-(N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino)butyl)-3-(3-(imidazol-1-yl)propyl)thiourea

11



5


- 10 1-(4-(N-(3,4-Dichlorobenzyl)-N-(pyridin-2-yl)amino)butyl)-3-(3-(imidazol-1-yl)propyl)thiourea



15


- 1-(3-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)propyl)-3-(3-(imidazol-1-yl)propyl)thiourea

12



5


1-(4-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)butyl)-3-(3-(imidazol-1-yl)propyl)thiourea



10


1-(3-(N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino)propyl)-3-(4-(N-(pyridin-2-yl)amino)propyl)thiourea

15




1-(4-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)butyl)-3-(3-(1H-imidazol-4-yl)propyl)thiourea

5



10

1-(5-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)pentyl)-3-(3-(1H-imidazol-4-yl)propyl)thiourea




15

1-(4-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)butyl)-3-(2-(1H-imidazol-4-yl)ethyl)thiourea


20

14



5


1-(2-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)ethyl)-3-(2-(1H-imidazol-4-yl)ethyl)thiourea




10

15 1-(2-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)ethyl)-3-(3-(1H-imidazol-4-yl)propyl)thiourea

15




- 5 1-(3-(N-(5-Bromopyridin-2-yl)-N-((naphth-1-yl)methyl)-amino)propyl)-3-(3-(1H-imidazol-4-yl)propyl)thiourea




10

- 1-(4-Aminobutyl)-3-(3-(N-(5-bromopyridin-2-yl)-N-((naphth-1-yl)methyl)amino)propyl)thiourea




15

1-(2-(N-(5-Nitropyridin-2-yl)-N-(3,4-dichlorobenzyl)amino) ethyl)-3-(3-(1H-imidazol-4-yl)propyl)thiourea




5

1-(2-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino) ethyl)-3-(3-(pyrrolidin-1-yl)propyl)thiourea



10


1-(2-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino) ethyl)-3-(3-dimethylaminopropyl)thiourea



15


1-(3-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino) propyl)-3-(4-(N-(pyridin-2-yl)amino)propyl)thiourea

5




1-(4-Aminobutyl)-3-[3-[N-(5-bromopyrid-2-yl)]-[N-(3,4-dichlorobenzyl)]aminopropyl]-thiourea

10




15 1-(3-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino) propyl)-3-(3-(pyrrolidin-1-yl)propyl)thiourea

18




- 5 1-[3-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino) propyl]-3-(2-(pyrid-2-yl)ethyl)thiourea



10


- 1-[3-[N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino]propyl]-3-[2-(1H-imidazol-4-yl)propyl]guanidine



15


19

1-[3-[N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino]propyl]-3-[2-(1H-imidazol-4-yl)ethyl]guanidine




5

1-[3-[N-(4-Bromobenzyl)-N-(pyridazin-2-yl)amino]propyl]-3-[3-(1H-imidazol-4-yl)propyl]guanidine



10


15 1-[3-[N-(4-Bromobenzyl)-N-(pyridin-3-yl)amino]propyl]-3-[3-(1H-imidazol-4-yl)ethyl]guanidine



20


1-[3-[N-(4-Bromobenzyl)-N-(pyrimidin-2-yl)amino]propyl]-3-[2-(1H-imidazol-4-yl)ethyl]guanidine

5



10

1-[3-[N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino]propyl]-3-[3-(imidazol-1-yl)propyl]guanidine




15


1-[3-[N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino]propyl]-3-[3-[N-(pyridin-2-yl)amino]propyl]guanidine

20

21




- 5 1-[3-[N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino]propyl]-3-[2-(pyridin-2-yl)ethyl]guanidine



10


- 15 1-[3-[N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino]propyl]-3-[3-(morpholin-4-yl)propyl]guanidine



15


1-Methyl-1-[3-(N,N-dimethylamino)propyl]-3-[3-[N-(4-bromobenzyl)-N-(pyridin-2-yl)amino]propyl]guanidine

5




1-[3-[N-(4-bromobenzyl)-N-(quinol-2-yl)amino]-propyl]-2-Benzoyl-3-[3-(1H-imidazol-4-yl)propyl]guanidine

10



N1-[3-(Imidazol-4(5)-yl)propyl]-N2-[3-[N-(4-bromobenzyl)-N-(pyridin-2-yl)-amino]propyl]-S-methylisothiurea

15



In a further embodiment of any one of the above first to eighth aspect the somatostatin receptor ligands of nonpeptide origin are agonists.

5

In a still further embodiment of any one of the above first to eighth aspect the somatostatin receptor ligands of nonpeptide origin are antagonists.

The somatostatin receptor ligands of nonpeptide origin of the invention can be employed to mediate the biological effects of somatostatin agonists or antagonists. It is predicted that compounds of formula Ia or Ib exhibit an improved bioavailability because they contain no amide bonds susceptible to cleavage by proteolytic enzymes. The increased resistance to proteolytic degradation combined with the reduced size of the compounds of the invention in comparison with known somatostatin agonists and antagonists is expected to possess beneficial properties such as increased peroral absorption, increased biological half-life, lack of immunogenicity, and the ability to cross the blood-brain barrier compared to that of the compounds suggested in the prior literature.

10

15

20

25

Compounds of formula Ia or Ib are believed to be useful for the development of pharmaceutical, therapeutic, and diagnostic techniques. Accordingly, the invention also provides methods for producing a prophylactic or therapeutic response in a mammal by administering to the mammal a pharmaceutically effective amount of one or more compounds of the invention. In accordance with preferred embodiments, the present invention provides methods for producing such responses by modulating the

activity of mammalian somatostatin receptors by administering an effective amount of one or more compounds of the invention.

- 5 In the above structural formulas and throughout the present specification, the following terms have the indicated meanings:

The C₁₋₆-alkyl groups specified above are intended to include those alkyl groups of the designated length in either a linear or branched or cyclic configuration. Examples of linear alkyl are methyl, ethyl, propyl, butyl, pentyl, and hexyl. Examples of
10 branched alkyl are isopropyl, sec-butyl, tert-butyl, isopentyl, and isohexyl. Examples of cyclic alkyl are C₃₋₆-cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

- 15 The alkoxy groups, preferably C₁₋₆-alkoxy groups specified above are intended to include those alkoxy groups of the designated length in either a linear or branched or cyclic configuration. Examples of linear alkyloxy are methoxy, ethoxy, propoxy, butoxy, pentoxy, and hexoxy. Examples of branched alkoxy are isopropoxy, sec-butoxy, tert-butoxy, isopentoxy, and isohexoxy. Examples of cyclic alkoxy are C₃₋₆-
20 cycloalkoxy such as cyclopropyloxy, cyclobutyloxy, cyclopentyloxy and cyclohexyloxy.


- In the present context, the term "aryl" is intended to include aromatic rings, such as carbocyclic and heterocyclic aromatic rings selected from the group consisting of
25 phenyl, naphthyl, thienyl, furyl, furanyl, pyridinyl, pyridyl, 1-H-tetrazol-5-yl, thiazolyl, imidazolyl, isoquinolinyl, indolyl, isoindolyl, piperidinyl, piperazinyl, pyridazinyl, pyrimidinyl, thiadiazolyl, pyrazolyl, oxadiazol, oxazolyl, isoxazolyl, thiopheneyl, quinolinyl, pyrazinyl, triazinyl, triazolyl, tetrazolyl or isothiazolyl, optionally substituted by one or more halogen, amino, hydroxy, carboxylic acid, carboxylic amide, nitrile, aldehyde, nitro, trihalogenomethyl, C₁₋₆-alkylketone, C₁₋₆-alkyl, C₁₋₆-alkoxy or aryl.
30

The term "halogen" is intended to include Chloro (Cl), Fluoro (F), Bromo (Br) and Iodo (I).

- 5 The compounds of the present invention may have one or more asymmetric centres and stereoisomers in the form of separated, pure or partially purified stereoisomers or racemic mixtures thereof are intended to be included in the scope of the invention.

10 General Method A


Reaction Scheme I:



Compounds of formula Ia or formula Ib may be prepared as shown in reaction scheme I starting with an arylhalogenide **1** which may be reacted with a diaminoalkyl **2** in an appropriate solvent such as pyridine and under nitrogen at reflux for an appropriate time. The excess diaminoalkyl and solvent may be removed in vacuo and an apolar solvent such as tetrahydrofuran may be added to precipitate the diaminoalkyl salt. The intermediate **3** may be obtained by distillation or chromatography by methods known in the art.

The intermediate **3** may be alkylated with an arylalkylhalogenide **4a** after treatment with a base such as sodium hydride under conditions known in the art to give a 1,1-disubstituted primary amine **5**. Then **5** in a solvent like tetrahydrofuran or ethanol may be reacted with an isothiocyanate **6**, prepared as shown in scheme 2, stirred overnight and concentrated in vacuo to afford a crude product **7a**. The isothiocyanate may be protected and deprotected according to methods described in the art (e.g. T.W. Greene, Protective Groups in Organic Synthesis, 2nd. edition, John Wiley and Sons, New York, 1991). The crude product **7a** may be purified by methods known for those skilled in the art such as chromatography, to yield the final product **7a** which is a compound of the general formula Ia. In the presence of a base such as sodium hydride, and an alkyl halide **4b** the compound **7b** which is a compound of the general formula Ib may be obtained.

Reaction Scheme II:



The isothiocyanate **6** as described in scheme I may be prepared from the appropriate protected primary amine **8** in a solvent like tetrahydrofuran and carbondisulfide in the presence of a reagent such as dicyclohexylcarbodiimide or other coupling reagents known in the literature under chilled conditions. The mixture may be stirred


overnight and the solvent removed and the residue may be triturated with ether to remove dicyclohexylthiourea. The remaining product may be distilled under vacuum or chromatographed using techniques known to those skilled in the art, to yield the isothiocyanate 6.

5

General Method B

Reaction Scheme III

10



15

Compounds of formula Ia may be prepared as shown in reaction scheme III starting with an appropriate amine 5, prepared as described in reaction scheme I, and an activated imine 8 in which R^3 may be benzoyl(-COPh) or nitrile (-CN) and R^4 may be thiomethoxy (-SCH₃), phenoxy (-OPh) or chloride (-Cl) in an appropriate solvent such as dimethylformamide or tetrahydrofuran at an appropriate temperature for an appropriate time to give the intermediate 9. The intermediate 9 may further react with an amine 2 in an appropriate solvent such as pyridine with or without a catalyst e.g.

20

silver salts (e.g. AgNO₃) at an appropriate temperature for an appropriate time to form the product **10** which is a compound of the general formula Ia.

When the compound **10** (in which R³ is an activating group such as benzoyl or nitrile) is treated with 1.5 M aqueous hydrogen chloride for an appropriate time at an appropriate temperature the compound **10** (in which R³ is hydrogen) may be formed which is a compound of the general formula Ia.

The intermediates in reaction scheme III may be protected and deprotected according to methods described in the art (e.g. T.W. Greene, Protective Groups in Organic Synthesis, 2nd. edition, John Wiley and Sons, New York, 1991).

The guanidine derivatives and their salts thus obtained can be isolated and purified by methods which are known by those skilled in the art.

Pharmacology

Compounds of the invention are preferred to the extent that they selectively and effectively are bound by somatostatin receptor subtypes permanently expressed in eukariotic cell lines. It will be recognized that the degree to which a compound is bound by a receptor is known as its binding affinity. The affinity of a compound is commonly expressed as the inhibitory concentration at which the compound is able to displace 50% of another compound already bound to the receptor (IC₅₀). In the case of ligand-binding studies at somatostatin receptors, the compound that is displaced is a radioactive agonist, e.g. ¹²⁵I-Tyr¹¹-SRIF-14, at the receptor. It is preferred in accordance with the present invention that a compound possess a clinically effective IC₅₀ in at least one mammal; that is, it should possess an IC₅₀ which is low enough to inhibit binding of radiolabelled agonist to somatostatin receptors while causing a minimum of unacceptable side effects in the mammal. As will be recognized, clinically effective concentrations vary depending on a number of factors, such as the pharmacokinetic characteristics and stability of the compound under study and thus must be deter-

mined empirically for each compound and each factor. In general, it is desired that the potency of a compound of the invention be as great as possible, preferable greater than or equal to the native somatostatin. Compounds displacing radiolabelled agonist at somatostatin receptors could belong to one of two classes, either agonists
5 or antagonists. Simple ligand-binding studies will not distinguish between these two classes. All five somatostatin receptor subtypes (ie. SSTR1, SSTR2, SSTR3, SSTR4 and SSTR5) have been shown to inhibit the activity of adenylyl cyclase via the G protein subunit G_i (Patel, Y.C. *et al.* Biochem. Biophys. Res. Commun., **198**:605-612, 1994). By direct activation of adenylyl cyclase by forskolin the inhibitory action of
10 somatostatin agonists could be employed. Compounds specifically reversing the inhibitory action of SRIF on cyclic AMP accumulation will be termed somatostatin receptor antagonists.

Those skilled in the art will appreciate that a wide variety of prophylactic, diagnostic,
15 and therapeutic treatments may be prepared from the compounds and compositions of this invention, due to agonism or antagonism at somatostatin receptors. For example, by administering an effective amount of compound of the invention, prophylactic or therapeutic responses can be produced in a human or some other type mammal. The diseases to be treated (either prophylactic or therapeutic) may be associated with an adverse condition in the retina and/or iris-ciliary body of a mammal,
20 which condition may be a high intraocular pressure (IOP) or deep ocular infections. The diseases to be treated are e.g. glaucoma, stromal keratitis, iritis, retinitis, cataract or conjunctivitis. It will be appreciated that the production of prophylactic or therapeutic responses includes the initiation or enhancement of desirable responses,
25 as well as the cessation or suppression of undesirable responses.

As can be seen, the present invention provides a variety of compounds which effectively and selectively are bound to somatostatin receptors. The compounds are capable of forming pharmaceutically acceptable salts with various inorganic and organic acids, and such salts are also within the scope of this invention. Examples of
30 such salts are acid addition salts including acetate, adipate, benzoate, benzene-

sulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, ethanesulfonate, fumarate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nitrate, oxalate, pamoate, persulfate, picrate, pivalate, propionate, succinate, sulfate, tartrate, tosylate, and undecanoate. The salts may be formed by conventional means, such as by reacting the free base form of the product with one or more equivalents of the appropriate acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water, which is later removed *in vacuo* or by freeze drying. The salts also may be formed by exchanging the anions of an existing salt for another anion on a suitable ion exchange resin.

In another aspect, the present invention relates to a pharmaceutical composition comprising, as an active ingredient, a compound of the general formula Ia or formula Ib or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.

Pharmaceutical compositions containing a compound of the present invention may be prepared by conventional techniques, e.g. as described in Remington's Pharmaceutical Sciences, 1985. The compositions may appear in conventional forms, for example capsules, tablets, aerosols, solutions, suspensions or topical applications.

The pharmaceutical carrier or diluent employed may be a conventional solid or liquid carrier. Examples of solid carriers are lactose, terra alba, sucrose, cyclodextrin, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid or lower alkyl ethers of cellulose. Examples of liquid carriers are syrup, peanut oil, olive oil, phospholipids, fatty acids, fatty acid amines, polyoxyethylene or water.

Similarly, the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.

If a solid carrier is used for oral administration, the preparation may be tableted, placed in a hard gelatin capsule in powder or pellet form or it can be in the form of a troche or lozenge. The amount of solid carrier will vary widely but will usually be from about 25 mg to about 1 g. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.

A typical tablet which may be prepared by conventional tableting techniques may contain:

Core:

Active compound (as free compound or salt thereof) 100 mg

Colloidal silicon dioxide (Aerosil) 1.5 mg

Cellulose, microcryst. (Avicel) 70 mg

Modified cellulose gum (Ac-Di-Sol) 7.5 mg

Magnesium stearate

Coating:

HPMC approx. 9 mg

*Mywacett 9-40 T approx. 0.9 mg

*Acylated monoglyceride used as plasticizer for film coating.

For nasal administration, the preparation may contain a compound of formula Ia or formula Ib dissolved or suspended in a liquid carrier, in particular an aqueous carrier, for aerosol application. The carrier may contain additives such as solubilizing agents, e.g. propylene glycol, surfactants, absorption enhancers such as lecithin (phosphatidylcholine) or cyclodextrin, or preservatives such as parabenes.

Generally, the compounds of the present invention are dispensed in unit dosage form comprising 50-200 mg of active ingredient together with a pharmaceutically acceptable carrier per unit dosage.

- 5 The dosage of the compounds according to this invention is suitably 1-500 mg/day, e.g. about 100 mg per dose, when administered to patients, e.g. humans, as a drug.

It has been demonstrated that compounds of the general formula Ia or formula Ib possess the ability to bind to human somatostatin receptors. The compounds may
10 therefor be used in the treatment of conditions which require high somatostatin receptor affinity.

Thus, in a particular aspect, the present invention relates to a pharmaceutical composition for binding to somatostatin receptors, the composition comprising, as an active ingredient, a compound of the general formula Ia or formula Ib or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
15

In a further aspect, the present invention relates to a method of binding to somatostatin receptors, the method comprising administering to a subject in need thereof an effective amount of a compound of the general formula Ia or formula Ib or a pharmaceutically acceptable salt thereof.
20

In a still further aspect, the present invention relates to the use of a compound of the general formula Ia or formula Ib or a pharmaceutically acceptable thereof for the preparation of a medicament for binding to the somatostatin receptors.
25

Those skilled in the art will appreciate that a wide variety of prophylactic, diagnostic, and therapeutic treatments may be prepared from the synthetic compounds and compositions of the invention, due in large part to the competition - that is, agonism
30 or antagonism - of these moieties with the naturally- occurring SRIF or SRIF-28. For

example, by administering an effective amount of a compound of the invention, prophylactic or therapeutic responses can be produced in a human or some other type mammal. Preferred responses are produced by modulating - that is, increasing, decreasing or otherwise modifying - the activity of the somatostatin receptor subtype SSTR4. It will be appreciated that the production of prophylactic or therapeutic responses includes the initiation or enhancement of desirable responses, as well as the cessation or suppression of undesirable responses.

The compounds of formula Ia or formula Ib may be administered in pharmaceutically acceptable acid addition salt form or, where appropriate, as a alkali metal or alkaline earth metal or lower alkylammonium salt. Such salt forms are believed to exhibit approximately the same order of activity as the free base forms.

Optionally, the pharmaceutical composition of the invention may comprise a compound of formula Ia or formula Ib combined with one or more compounds exhibiting a different activity, e.g., an antibiotic or other pharmacologically active material.

The route of administration may be any route which effectively transports the active compound to the appropriate or desired site of action, such as oral, nasal, pulmonary, transdermal or parenteral, the oral route being preferred.

EXAMPLES:

The process for preparing compounds of formula Ia or formula Ib and preparations containing them is further illustrated in the following examples, which however, are not to be construed as limiting.

The structures of the compounds are confirmed by either elemental analysis (MA) nuclear magnetic resonance (NMR) or mass spectrometry (MS). NMR shifts (δ) are given in parts per million (ppm) and only selected peaks are given. m.p. is melting point and is given in °C and is not corrected. Column chromatography was carried

out using the technique described by W.C. Still et al, J. Org. Chem. 1978, 43, 2923-2925 on Merck silica gel 60 (Art 9385). Compounds used as starting materials are either known compounds or compounds which can readily be prepared by methods known per se.

5

Abbreviations:

TLC: thin layer chromatography

DMSO: dimethylsulfoxide

min: minutes

10 h: hours

HPLC-Analysis:**Method A.**

15

The RP-HPLC analysis was performed using UV detection at 254nm and a Lichrosorp RP-18 5mM column, which was eluted at 1ml/minute. The column was equilibrated with 20% acetonitrile in a buffer consisting of 0.1M ammonium sulfate, which was adjusted to pH 2.5 with 4M sulfuric acid and eluted by a gradient of 20% to 80% acetonitrile in the same buffer over 30 minutes. The gradient was then extended to 100% acetonitrile over 5 minutes followed by isocratic elution with 100% acetonitrile for 6 minutes.

20

25 **Biological assays**

30

The affinity of somatostatin receptor ligands of nonpeptide origin according to the invention (including the compounds covered by formula Ia and Ib) to the somatostatin receptor proteins selected from SST1, SST2, SST3, SST4 and SST5, may be detected using the assays described below. The skilled person will know which adjustments/modifications to make in order to screen for specific ligands having affinity

to one or more of the SST receptor subtypes 1-5. Moreover, in order to screen large compound libraries to find the present ligands, conventional techniques (see e.g. Amersham™ SPA Technology) known to the skilled person may be used to modify the assays. One way of producing the present ligands is to provide a compound library of nonpeptide origin using conventional techniques (see e.g. Combinatorial chemistry in the discovery and development of drugs. Doyle, P.M., Journal Of Chemical Technology And Biotechnology (1995) Vol. 64, 317-24) well-known to the skilled person, and screen for such ligands using the assays described below optionally with modifications, thereby providing somatostatin receptor ligands according to the invention.

Cell lines expressing SST receptor subtypes:

BHK cells (tk- ts13, ATCC CRL# 1632) and HEK 293 cells (ATCC CRL# 1573) were grown to 20-40% confluency in a tissue culture dish in Dulbeccos Modified Eagle Medium (DMEM) containing 1% penicillin / streptomycin , 10% foetal bovine serum, and 1% Glutamax™. Prior to transfection, the cells were washed twice with calcium-free PBS after which 20 ml of serum-free DMEM was added to the cells.

Transfection was carried out as described previously (product description: Lipofectamin, Gibco BRL cat. no. 18324-012). Briefly, 10 µg of cDNA encoding a SST receptor subtype inserted into the mammalian expression vector pcDNA3 (Invitrogen) was diluted in 300 µl of sterile water. 30 µg of Lipofectamin was diluted in 300 µl of sterile water. The cDNA and Lipofectamin solutions were mixed and left at room temperature for 15 minutes. The Lipofectamin/cDNA mixture was added drop-wise to the cells (HEK 293 cells for SST₂, BHK for the other receptor subtypes) while gently swirling the plates. The cells were then incubated for 16-24 hours, after which the medium was replaced with standard medium containing 1 mg/ml Geneticin (G-418 sulfate). Resistant colonies appearing after 1-2 weeks were isolated and propagated for further characterization.

Binding assay:


Cells expressing individual SST receptor subtypes were resuspended in buffer (50 mM Tris-HCl (pH 7.4), 1 mM EGTA, 5 mM MgCl₂), and homogenised. Membranes were washed twice in buffer by homogenisation and centrifugation. Final membrane pellets were resuspended at a protein concentration of 125 µg/ml in buffer. Binding assays using 75 pM ¹²⁵I-Tyr¹¹-SRIF (Amersham, IM-161) were done in duplicates in minisorb polypropylene tubes in a volume of 250 µl. The assays were incubated at 30-37 °C for 30-90 min depending on receptor subtype. Binding was terminated by filtration through Whatman GF/B glass fiber filters pre-soaked for 4 hrs. in 0.5% polyethyleneimine and 0.1% BSA. Filters were washed three times with 5 ml ice-cold 0.9% saline and counted in a Packard Cobra II Gamma Counter.

Functional assay:

Cells expressing human SST receptors were seeded in 24-well tissue culture multi-dishes at 200,000 cells/well and grown for 16-20 hours. The medium was removed, and fresh DMEM medium, supplemented with 1) 1 mM 3-isobutyl-1-methylxanthine (IBMX), 2) 10 µM forskolin or medium, and 3) medium, SRIF, SST analogue, or compound was added. The plates were incubated for 15-30 min at 37°C, the reaction medium removed and the cells lysed with 0.1 M sodium hydroxide. Following neutralisation with 0.1 M hydrochloric acid an aliquot was removed for cAMP determination using Amersham SPA RIA (RPA 538).

EXAMPLE 1

1-(3-(N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino)propyl)-3-(3-(1H-imidazol-4-yl)propyl)thiourea dihydrochloride



To a solution of propane-1,3-diamine (310 ml, 3.63 mol) in dry pyridine (75 ml) kept
5 under an atmosphere of nitrogen 2-bromopyridine (70 ml, 0.73 mol) was added. The
reaction mixture was heated at reflux for 18 h, cooled and the volatiles evaporated in
vacuo. To the residue was added tetrahydrofuran (1 l) and the precipitate was filtered
off and washed with tetrahydrofuran (0.5 l). The solvent was evaporated in vacuo
and the residue purified by distillation at 95-97 °C and 2×10^{-2} mbar affording 83.37 g
10 (76 %) of N-(pyridin-2-yl)propane-1,3-diamine.

¹H NMR (200 MHz, DMSO-*d*₆) δ 1.20 (bs, 2H, NH₂), 1.74 (p, 2H), 2.82 (t, 2H), 3.34
(q, 2H, CH₂-NH), 4.86 (bs, 1H, NH), 6.35 (dt, 1H), 6.51 (ddd, 1H), 7.37 (ddd, 1H),
15 8.04 (ddd, 1H).

To a mixture of sodium hydride (5.86 g, 60 % dispersion in mineral oil, 0.1415 mol) in
dry dimethylsulfoxide (250 ml) was slowly added a solution of N-(pyridin-2-
20 yl)propane-1,3-diamine (20 g, 0.1323 mol) in dry dimethylsulfoxide (50 ml) at room
temperature under an atmosphere of nitrogen. The reaction mixture was stirred until
gas evolution was ceased. A solution of 4-bromobenzylbromide (36.09 g, 0.1415
mol) in dry dimethylsulfoxide (100 ml) was slowly added at room temperature. The
reaction mixture was stirred for 48 h at room temperature. The reaction mixture was
25 poured onto ice water (500 ml) and extracted with ethyl acetate (3 x 250 ml). The
combined organic extracts were washed with water (3 x 150 ml), dried (MgSO₄),
filtered and the solvent evaporated in vacuo. The residue (40.56 g) was washed with

n-heptane (30 ml) which afforded 36.77 g of crude N-(4-bromobenzyl)-N-(pyridin-2-yl)propane-1,3-diamine. 20 g crude product was purified by column chromatography on silica gel (900 ml) using dichloromethane/methanol/triethylamine 9:0.5:0.5 as eluent affording 13.75 g (70 %) of N-(4-bromobenzyl)-N-(pyridin-2-yl)propane-1,3-diamine as an oil.

¹H NMR (200 MHz, CDCl₃) δ 1.64 (s, 2H, NH₂), 1.74 (t, 2H), 2.72 (t, 2H), 3.60 (t, 2H, CH₂-N), 4.67 (s, 2H, CH₂-Ph), 6.41 (d, 1H), 6.53 (dd, 1H), 7.07 (d, 2H), 7.33 - 7.41 (m, 3H), 8.13 (dt, 1H).

To a solution of N,N-dicyclohexylcarbodiimide (2.08 g, 10 mmol) in dry tetrahydrofuran (20 ml) was slowly added at -10 °C a solution of N-(4-bromobenzyl)-N-(pyridin-2-yl)propane-1,3-diamine (3.20 g, 10 mmol) and carbondisulfide (4.3 ml, 70 mmol) in dry tetrahydrofuran (20 ml) under an atmosphere of nitrogen. The mixture was stirred at -10 °C for 3 h and for 48 h at room temperature. The reaction mixture was filtered and the solvent evaporated *in vacuo*. The residue (5.29 g) was extracted with diethyl ether (3 x 20 ml) and the combined organic extracts were evaporated *in vacuo* affording 3.2 g (88 %) of N-(4-bromobenzyl)-N-(3-isothiocyanatopropyl)-N-(pyridin-2-yl)amine as an oil.

TLC: R_f = 0.72 (SiO₂; ethyl acetate/n-heptan = 1:1).

¹H NMR (200 MHz, CDCl₃) δ 2.00 (q, 2H), 3.57 (t, 2H), 3.68 (t, 2H), 4.66 (s, 2H), 6.41 (d, 1H), 6.58 (dd, 1H), 7.07 (d, 2H), 7.35 - 7.43 (m, 3H), 8.15 (dd, 1H).

N-(4-bromobenzyl)-N-(3-isothiocyanatopropyl)-N-(pyridin-2-yl)amine (1 g, 2.76 mmol) and 3-(1-triphenylmethylimidazol-4-yl)propylamine (1.014 g, 2.76 mmol) were dissolved in chloroform (10 ml) and heated at reflux for 4 h. The solvent was removed by evaporation *in vacuo* and the residue (3.09 g) purified by column chromatography on silica gel (400 ml) using ethyl acetate/methanol/ triethylamine

9:0.5:0.5 as eluent affording 1.59 g (80 %) of pure 1-[3-(1-triphenylmethylimidazol-4-yl)propyl]-3-[3-[N-(4-bromobenzyl)-N-(pyridin-2-yl)amino]propyl]thiourea.

TLC: R_f = 0.59 (SiO₂; ethyl acetate/methanol/triethylamine = 9:0.5:0.5).

5

¹H NMR (200 MHz, CDCl₃) δ 1.90 (m, 6H), 2.62 (t, 2H), 3.44 - 3.68 (m, 6H), 4.55 (s, 2H, CH₂-Ph), 6.33 (d, 1H), 6.49 (dd, 1H), 6.56 (s, 1H), 6.98 - 7.11 (m, 9H), 7.30 - 7.39 (m, 11H), 8.06 (d, 1H).

- 10 To a solution of the above thiourea (1.59 g, 2.215 mmol) in ethanol (50 ml), 1 N hydrochloric acid (16 ml) was added and the reaction mixture was heated to 50 °C for 10 h. The cooled reaction mixture was washed with diethyl ether (3 x 30 ml) and the aqueous phase evaporated in vacuo. The residue was extracted with absolute ethanol (3 x 20 ml) and evaporated in vacuo followed by drying in vacuo affording
- 15 1.23 g (99 %) of the title compound as an amorphous powder.


¹H NMR (200 MHz, MeOD-d₃) δ 2.0 (m, 4H), 2.77 (t, 2H), 3.57 (m, 4H), 3.76 (t, 2H), 4.90 (s, 2H, CH₂-Ph), 6.99 (t, 1H), 7.19 (d, 2H), 7.26 (d, 1H), 7.36 (s, 1H), 7.50 (d, 2H), 7.94 (d, 1H), 8.02 (dd, 1H), 8.78 (d, 1H).

20

EXAMPLE 2

1-(3-(N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino)propyl)-3-(3-(morpholin-4-yl)propyl)thiourea

25



To a solution of N-(4-bromobenzyl)-N-(pyridin-2-yl)propane-1,3-diamine (1.0 g, 3.123 mmol) in chloroform (40 ml) was added 3-morpholinopropyl isothiocyanate (593 mg, 3.123 mmol) and the reaction mixture was stirred for 20 h at reflux temperature. To the reaction mixture was added 10 drops of 3-morpholinopropyl isothiocyanate and the reaction mixture was stirred for an additional 4 h at reflux temperature. The volatiles were evaporated in vacuo and the residue (2.05 g) was dissolved in ethyl acetate (20 ml) and left over night at room temperature. The precipitate was filtered off and washed with ethyl acetate and dried affording 1.20 g (76 %) of the title compound as a solid.

TLC: R_f = 0.39 (SiO₂; Ethyl acetate/Methanol/Triethylamine = 90:5:5)


M.p. 121-123 °C

HPLC retention time = 6.68 minutes (5 mM C18 4 x 250 mm column, eluting with 25% acetonitrile/0.1 N aqueous ammonium sulphate, pH = 2.5, at room temperature)

¹H-NMR (200 MHz, CDCl₃) δ 1.84 (m, 4H), 2.49 (m, 6H), 3.53 (m, 4H), 3.71 (m, 6H), 4.56 (s, 2H, CH₂-Ph), 6.36 (d, 1H), 6.57 (m, 1H), 7.04 (d, 1H), 7.22 (bs, 1H), 7.32 - 7.45 (m, 3H), 7.91 (bs, 1H), 8.15 (d, 1H).

EXAMPLE 3

1-(3-(N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino)propyl)-3-(3-N,N-dimethylaminopropyl)thiourea



To a solution of N-(4-bromobenzyl)-N-(pyridin-2-yl)propane-1,3-diamine (1.0 g,
5 3.123 mmol) in chloroform (40 ml) was added 3-(dimethylamino)propyl
isothiocyanate (460 mg, 3.123 mmol) and the reaction mixture was stirred for 5 h at
reflux temperature. The volatiles were evaporated in vacuo and the residue (1.69 g)
was purified by column chromatography on silica gel (180 ml) using ethyl
acetate/methanol/triethylamine 7:2.5:0.5 as eluent affording (1.41 g) of a syrup which
10 was crystallised from n-heptane affording 1.23 g (85 %) of the title compound as a
solid.

TLC: R_f = 0.39 (SiO_2 ; Ethyl acetate/Methanol/Triethylamine = 70:25:5)

15 M.p. 79-81 °C


HPLC retention time = 6.09 minutes (5 mM C18 4 x 250 mm column, eluting with 25
% acetonitrile/0.1 N aqueous ammonium sulphate, pH = 2.5, at room temperature)

20 $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 1.72 (p, 2H), 1.84 (p, 2H), 2.19 (s, 6H), 2.40 (t, 2H),
3.48 (bs, 4H), 3.68 (t, 2H), 4.59 (s, 2H, $\text{CH}_2\text{-Ph}$), 6.37 (d, 1H), 6.56 (dd, 1H), 7.04 (d,
2H), 7.38 (m, 3H), 8.17 (bd, 1H).

EXAMPLE 4

1-[3-[N-(4-bromobenzyl)-N-(quinolin-2-yl)amino] propyl]- 2-Benzoyl-3-[3-(1H-imidazol-4-yl)propyl]guanidine

5



To a solution of propane-1,3-diamine (65.1 ml, 0.764 mol) in dry pyridine (25 ml) kept
10 under an atmosphere of nitrogen 2-chloro-quinoline (25 g, 0.153 mol) was added.
The reaction mixture was heated at reflux temperature for 18 h. To the cooled
reaction mixture was added tetrahydrofuran (100 ml) and the precipitate was filtered
off and washed with tetrahydrofuran (2 x 50 ml). The solvent was evaporated in
vacuo and the residue purified by distillation at 154 °C and 2.5×10^{-2} mbar affording
15 25.34 g (82 %) of N-(quinolin-2-yl)propane-1,3-diamine as a crystallising oil.

^1H NMR (200 MHz, CDCl_3) δ 1.37 (bs, 2H, NH_2), 1.77 (p, 2H), 2.83 (t, 2H), 3.59 (q,
2H, $\text{CH}_2\text{-NH}$), 5.22 (bs, 1H, NH), 6.59 (d, 1H), 7.17 (dt, 1H), 7.49 (m, 2H), 7.66 (d,
1H), 7.76 (d, 1H).

20

To a mixture of sodium hydride (2.64 g, 60 % dispersion in mineral oil, 63.79 mmol)
in dry dimethylsulfoxide (100 ml) was slowly added a solution of N-(quinolin-2-
yl)propane-1,3-diamine (12 g, 56.62 mmol) in dry dimethylsulfoxide (25 ml) at room
25 temperature under an atmosphere of nitrogen. The reaction mixture was stirred until

gas evolution was ceased. To the resulting mixture a solution of 4-bromobenzylbromide (16.27 g, 63.79 mmol) in dry dimethylsulfoxide (50 ml) was slowly added at room temperature. The reaction mixture was stirred for 4 days at room temperature poured on to ice water (800 ml) and extracted with ethyl acetate (5 x 150 ml). The combined organic extracts were washed with water (4 x 150 ml), dried (MgSO₄), filtered and the solvent evaporated in vacuo. The residue (22.27 g) was washed with n-heptane (30 ml) which afforded 20.41 g of crude N-(4-bromobenzyl)-N-(quinolin-2-yl)propane-1,3-diamine which was purified by column chromatography on silica gel (900 ml) using a mixture of dichloromethane/methanol/triethylamine 9:0.5:0.5 as eluent affording 13.9 g (63 %) of N-(4-bromobenzyl)-N-(quinolin-2-yl)propane-1,3-diamine as an oil.

¹H NMR (200 MHz, CDCl₃) δ 1.76 (m, 4H), 2.74 (t, 2H), 3.78 (t, 2H), 4.80 (s, 2H), 6.77 (d, 1H), 7.16 (m, 3H), 7.41 (d, 2H), 7.55 (m, 2H), 7.67 (d, 1H), 7.81 (d, 1H).

To a solution of the above amine (8.0 g, 21.604 mmol) in dichloromethane (100 ml) was added N-benzoyl-dimethyldithioimidocarbonate (4.87 g, 21.604 mmol) and the reaction mixture was stirred at room temperature for 20 h. The solvent was evaporated in vacuo and the residue was purified by column chromatography on silica gel (900 ml) using a mixture of ethyl acetate and heptane 1:2 as eluent affording 10.92 g (92 %) of 1-benzoyl-3-[3-[N-(4-bromobenzyl)-N-(quinolin-2-yl)amino]-propyl]-2-methylisothiourea.

To a solution of the above isothiourea (5.0 g, 9.133 mmol) in dry pyridine (70 ml) was added 3-(1H-imidazol-4-yl)propyl amine (1.26 g, 10.05 mmol) and the resulting mixture was stirred at reflux temperature for 10 h followed by stirring at room temperature for 48 h. The solvent was evaporated in vacuo and the residue was purified by column chromatography on silica gel (600 ml) using a mixture of dichloromethane/methanol/triethylamine 9:0.5:0.5 as eluent affording 3.31 g (58 %) of the title compound as an amorphous solid.


¹H NMR (200 MHz, CDCl₃) δ 1.84 (bs, 2H), 2.01 (m, 2H), 2.59 (m, 2H), 3.24 - 3.70 (m, 4H), 3.80 (t, 2H), 4.78 (s, 2H), 6.69 (s, 1H), 6.76 (d, 1H), 7.09 (d, 2H), 7.22 (dt, 2H), 7.29 - 7.80 (m, 9H), 8.18 (d, 2H).

- 5 HPLC retention time = 26.10 minutes (5 mM C18 4 x 250 mm column, eluting with a gradient of 15 % acetonitrile/0.1 N aqueous ammonium sulphate to 25 % acetonitrile/0.1 N aqueous ammonium sulphate, pH = 2.5, over 10 minutes at room temperature).

10

EXAMPLE 5

- 15 1-[3-[N-(4-Bromo-benzyl)-N-(quinolin-2-yl)amino]-propyl]- 3-[3-(1*H*-imidazol-4-yl)propyl]guanidine trihydrochloride



- 20 The above benzoyl guanidine (120 mg, 0.19 mmol) was dissolved in 1.5 N hydrochloric acid (3.6 ml) and stirred at 100 °C for 16 h in an ampoule. The cooled reaction mixture was washed with diethyl ether (2 x 2 ml) and the aqueous phase was evaporated in vacuo. The residue was dissolved in ethanol (10 ml) and evaporated in vacuo. This evaporation procedure was repeated twice. This afforded
- 25 116 mg (98 %) of the title compound as an amorphous solid.

¹H NMR (200 MHz, MeOD-d₃) δ 1.97 (m, 2H), 2.10 (m, 2H), 2.84 (t, 2H), 3.30 (m, 2H), 3.40 (t, 2H), 4.00 (m, 2H), 5.11 (s, 2H), 7.25 (d, 2H), 7.40 (d, 2H), 7.55 (m, 3H), 7.80 (t, 1H), 7.90 (d, 1H), 8.30 (d, 1H), 8.90 (d, 1H), 8.80 (s, 1H).


5 HPLC retention time = 7.15 minutes (5 mM C18 4 x 250 mm column, eluting with a gradient of 16 % acetonitrile/0.1 N aqueous ammonium sulphate to 25 % acetonitrile/0.1 N aqueous ammonium sulphate, pH = 2.5, over 10 minutes at room temperature).

10

EXAMPLE 6

1-(2-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino) ethyl)-3-(3-(1H-imidazol-4-yl)propyl)thiourea

15



A mixture of 2,5-dibromopyridine (10.0 g, 42.2 mmol) and pyridine (4.24 g, 53.6 mmol) in 1,2-diaminoethane (43 mL) was refluxed under nitrogen for 18 h. The reaction mixture was evaporated under reduced pressure, cooled, and the resulting residue was treated with THF (150 mL) to yield a white precipitate. The precipitate was filtered and washed with additional THF (100 mL). Evaporation of the filtrate afforded a brown oil which was vacuum distilled to give 6.48 g (71%) N-1-(5-bromopyrid-2-yl)ethane-1,2-diamine as a light yellow oil.

bp 134-142°C (0.6 mm).

¹H NMR (90 MHz CDCl₃)d 1.33 (s, 2 H, NH₂), 2.92 (t, 2 H), 3.29 (m, 2 H), 5.22 (br s, 1 H, NH), 6.31 (d, J = 9 Hz, 1 H, pyridine H-3), 7.44 (dd, J = 2.7 Hz, 9 Hz, 1 H, pyridine H-4), 8.09 (d, J = 2.5 Hz, 1 H, pyridine H-6).

¹³C NMR (90 MHz CDCl₃)d 41.22, 44.74, 106.72, 108.67, 139.55, 148.54, 148.70.

A 60 % mineral oil dispersion of sodium hydride (0.584 g, 14.6 mmol) and N-1-(5-bromopyrid-2-yl)ethane-1,2-diamine (3.00 g, 13.9 mmol) in DMSO (30 mL) was stirred for 2 h under nitrogen. The suspension was cooled to 0-5 °C and treated dropwise with 3,4-dichlorobenzyl chloride (2.71 g, 13.9 mmol) in DMSO (15 mL). After stirring overnight at room temperature, the reaction mixture was poured into 200 mL of an ice-water mixture. The mixture was extracted with ethyl acetate (3 x 75 mL), and the combined ethyl acetate extracts were washed with water (2 x 50 mL), dried (Na₂SO₄), filtered, and evaporated to yield an oil. Flash chromatography on silica gel using CH₂Cl₂ 90: CH₃OH 5: Et₃N 5 as the solvent system gave 3.5 g (67%) of N-1-(5-bromopyrid-2-yl)-1-(3,4-dichlorobenzyl)ethane-1,2-diamine as a yellow oil.

¹H NMR (90 MHz CDCl₃)d 1.45 (s, 2 H, NH₂), 2.92 (t, 2 H, NCH₂), 3.57 (m, 2 H, CH₂NH₂), 4.72 (s, 2 H, ArCH₂), 6.39 (d, J = 9 Hz, 1 H, pyridine H-3), 7.32 (m, 4 H, ArH), 8.16 (d, J = 2 Hz, 1 H, pyridine H-6).

¹³C NMR (90 MHz CDCl₃)d 39.82, 51.47, 51.95, 107.00, 107.27, 126.23, 128.77, 130.62, 131.04, 132.73, 138.85, 139.77, 148.66, 156.62.

A mixture of dicyclohexylcarbodiimide (DCC) (2.74 g, 13.2 mmol) and carbon disulfide (10.1 g, 132.6 mmol) in THF (30 mL) was cooled to -10 °C in an ice-salt bath and treated dropwise with a solution of N-1-(5-bromopyrid-2-yl)-1-(3,4-dichlorobenzyl)ethane-1,2-diamine (5.00 g, 13.2 mmol) in THF (20 mL). The reaction mixture was allowed to warm to room temperature and was stirred overnight under

nitrogen. Removal of the solvent under reduced pressure afforded a white solid. The solid was triturated with diethyl ether (200 mL), and the dicyclohexylthiourea was removed by filtration. The filtrate was evaporated, and acetonitrile (100 mL) was added to the resulting residue. The remaining dicyclohexyl-thiourea was filtered, and the filtrate was evaporated under vacuum to afford an oil. Flash chromatography on silica gel using CH₂Cl₂ 50: hexane 50: Et₃N 1 gave 4.31 g (78%) of 2-[N-(5-bromopyrid-2-yl)-N-(3,4-dichlorobenzyl)] aminoethyl isothiocyanate as a white solid. Recrystallization from diethyl ether/hexane gave an analytical sample.
mp 83-85 °C.

¹H NMR (90 MHz CDCl₃) δ 3.84 (m, 4 H), 4.69 (s, 2 H, ArCH₂), 6.33 (d, J = 8.3 Hz, 1 H, pyridine H-3), 7.40 (m, 4 H), 8.20 (d, J = 2 Hz, 1 H, pyridine H-6).

¹³C NMR (90 MHz CDCl₃) δ 43.34, 49.19, 52.71, 107.70, 108.19, 125.74, 128.34, 130.83, 140.10, 148.71, 155.65.

Anal.

Calcd for C₁₅H₁₂BrCl₂N₃S: C, 47.01; H, 3.16; N, 14.62.

Found: C, 46.93; H, 3.32; N, 14.56.

A suspension of 3-[1-(triphenylmethyl)imidazol-4-yl]propylamine¹ (0.87 g, 2.64 mmol) in THF (40 mL) was stirred under a nitrogen atmosphere at 0-5 °C and treated dropwise with a solution of 2-[N-(5-bromopyrid-2-yl)-N-(3,4-dichlorobenzyl)]aminoethyl isothiocyanate (1.10 g, 2.64 mmol) in THF (15 mL). The reaction mixture was allowed to warm to room temperature and was stirred overnight. TLC on silica gel using EtOAc 90: CH₃OH 5: Et₃N 5 indicated that considerable starting material remained. The reaction mixture was refluxed for 24 h, and the solvent was removed under reduced pressure to yield a white foam. Flash chromatography on silica gel using EtOAc 90: CH₃OH 5: Et₃N 5 as the solvent afforded 1.72 g (87%) of the trityl-protected thiourea as a colorless oil. The oil was suspended in 2 N HCl (40 mL) and was refluxed for 8 h under nitrogen. The

precipitated triphenylmethanol was filtered, and the filtrate was evaporated under reduced pressure to yield a foam. The foam was suspended in 1 N NaOH (60 mL) and extracted with EtOAc (3 x 75 mL). The combined ethyl acetate extracts were washed with water (2 x 50 mL), dried (Na_2SO_4), filtered, and evaporated to yield upon
5 trituration with hexane 765 mg (57%) the title compound as a white hygroscopic foam.

^1H NMR (90 MHz CDCl_3)d 1.90 (m, 2 H), 2.64 (m, 6 H), 3.55 (m, 6 H), 4.62 (s, 2 H, ArCH_2), 6.44 (d, $J = 9$ Hz, 1 H, pyridine H-3), 7.20-7.55 (m, 8 H, $\text{NHC}=\text{SNH}$ and ArH),
10 8.09 (d, $J = 2.5$ Hz, 1 H, pyridine H-6).

^{13}C NMR (90 MHz CDCl_3)d 23.49, 28.87, 42.42, 43.50, 47.84, 51.79, 107.51, 108.19, 115.99, 126.01, 128.50, 130.78, 131.31, 132.89, 134.35, 137.22, 137.98, 140.26, 148.04, 156.62, 181.75.


Anal.

Calcd for $\text{C}_{21}\text{H}_{23}\text{BrCl}_2\text{N}_8\text{S}$: C, 46.50; H, 4.28; N, 15.50.

Found: C, 45.13; H, 5.00; N, 16.22

20 EXAMPLE 7

1-(2-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino) ethyl)-3-(2-(1H-imidazol-4-yl)ethyl)thiourea



A suspension of histamine (320 mg, 2.88 mmol) in THF (40 mL) was treated with a solution of 2-[N-(5-bromopyrid-2-yl)-N-(3,4-dichlorobenzyl)]aminoethyl isothiocyanate (1.20 g, 2.88 mmol) in THF (15 mL). The reaction mixture was stirred for 48 h under a nitrogen atmosphere, and the solvent was removed under reduced pressure to afford a foam. Flash chromatography on silica gel using a solvent system of EtOAc 90: CH₃OH 5: concentrated NH₄OH 5 gave 987 mg (67%) of the title compound as a white foam.

mp 72-78 °C.

¹H NMR (90 MHz CDCl₃) δ 2.85 (m, 2 H), 3.68 (m, 6 H), 4.59 (s, 2 H, ArCH₂), 6.40 (d, 1 H, pyridine H-3), 6.80-7.50 (m, 9 H, NHC=SNH and ArH), 8.02 (d, 1 H, pyridine H-6).

¹³C NMR (90 MHz CDCl₃) δ 27.66, 42.81, 47.74, 51.80, 107.49, 108.19, 116.16, 125.96, 130.84, 131.33, 132.95, 134.90, 135.55, 137.82, 140.32, 148.12, 156.63, 181.71.


Anal.

Calcd for C₂₀H₂₁BrCl₂N₆S: C, 45.46; H, 4.01; N, 15.91.

Found: C, 44.90; H, 4.24; N, 15.79

EXAMPLE 8

1-(2-(N-(5-Nitropyridin-2-yl)-N-(3,4-dichlorobenzyl)amino) ethyl)-3-(3-(1H-imidazol-4-yl)propyl)thiourea



In a similar manner as described for the synthesis of N-1-(5-bromopyrid-2-yl)-1-(3,4-dichlorobenzyl)ethane-1,2-diamine, sodium hydride (0.692 g, 17.3 mmol), N-1-(5-nitropyrid-2-yl)ethane-1,2-diamine (3.00 g, 16.5 mmol), and 3,4-dichlorobenzyl chloride (3.22 g, 16.5 mmol) in DMSO (25 mL) gave an oil. Flash chromatography on silica gel using EtOAc 60: CH₃OH 40: concentrated NH₄OH 1 as the solvent yielded 2.84 g (51%) of N-1-(5-nitropyrid-2-yl)-1-(3,4-dichlorobenzyl)ethane-1,2-diamine as an oil.

¹H NMR (90 MHz CDCl₃) δ 1.35 (br s, 2 H, NH₂), 3.68 (t, 2 H), 4.88 (s, 2 H), 6.55 (d, J = 9.6 Hz, 1 H, pyridine H-3), 7.30 (m, 3 H), 8.23 (dd, J = 2.7 Hz, 9.3 Hz, 1 H, pyridine H-4), 9.08 (d, J = 2.9 Hz, 1 H, pyridine H-6).

¹³C NMR (90 MHz CDCl₃) δ 39.71, 51.74, 52.12, 104.61, 126.23, 128.83, 130.83, 133.11, 137.33, 146.49.

Using a similar procedure as described for the synthesis of 2-[N-(5-bromopyrid-2-yl)-N-(3,4-dichlorobenzyl)]aminoethyl isothiocyanate, DCC (1.70 g, 8.21 mmol), carbon disulfide (6.70 g, 88 mmol), and N-1-(5-nitropyrid-2-yl)-1-(3,4-dichlorobenzyl) ethane-1,2-diamine (2.80 g, 8.21 mmol) in THF (60 mL) gave a dark yellow solid. Flash chromatography on silica gel using hexane 50: CH₂Cl₂ 50: Et₃N 1 as the solvent system gave 2.20 g (71%) of 2-[N-(3,4-dichlorobenzyl)-N-(5-nitropyrid-2-yl)]aminoethyl isothiocyanate as a yellow solid.

mp 104-106 °C

¹H NMR d 3.94 (m, 4 H), 4.85 (s, 2 H, ArCH₂), 6.49 (d, J = 10 Hz, 1 H, pyridine H-3),
7.29 (m, 3 H, ArH), 8.23 (dd, J = 2.7 Hz, 9.3 Hz, 1 H, pyridine H-4), 9.08 (d, J = 2 Hz,
5 1 H, pyridine H-6).

Anal.

Calcd for C₁₅H₁₂Cl₂N₄O₂S: C, 47.01; H, 3.16; N, 14.62.

Found: C, 46.93; H, 3.32; N, 14.56.

10

A suspension of 3-[1-(triphenylmethyl)imidazol-4-yl]propylamine (959 mg, 2.61 mmol) in THF (20 mL) was cooled to 0-5 °C in an ice-water bath and treated dropwise with 2-[N-(3,4-dichloro benzyl)-N-(5-nitropyrid-2-yl)]aminoethyl isothiocyanate (1.00 g, 2.61 mmol) in THF (40 mL). After stirring overnight at room temperature under a
15 nitrogen atmosphere, the solvent was removed under reduced pressure to yield 2.1 g of a yellow foam. The intermediate trityl-protected thiourea was suspended in 1 N HCl (35 mL) and refluxed for 1.5 h. The solution was filtered, extracted with diethyl ether (2 x 200 mL), basified with 6 N NaOH, and extracted with EtOAc (3 x 100 mL). The combined ethyl acetate extracts were washed with water (3 x 100 mL), dried
20 (Na₂SO₄), and evaporated under vacuum to yield a foam. Flash chromatography on silica gel using a solvent system of CH₂Cl₂ 90: CH₃OH 10:concentrated NH₄OH 1 yielded 500 mg (38%) of the title compound as a yellow foam.

¹H NMR (DMSO-d₆) d 1.72 (m, 2 H), 3.50 (m, 8 H), 4.93 (s, 2 H, ArCH₂), 6.75 (s, 1 H),
25 7.35 (m, 7 H), 8.22 (dd, 1 H, pyridine H-4), 8.97 (d, J = 2.7 Hz, pyridine H-6).

¹³C NMR (90 MHz CDCl₃)d 23.14, 28.99, 42.05, 42.40, 48.01, 51.58, 105.27, 126.45, 128.89, 130.89, 133.17, 133.98, 146.28, 160.58, 181.46.

30 Anal.


Calcd for C₂₁H₂₃Cl₂N₇O₂S: C, 49.60; H, 4.57; N, 19.29.

Found: C, 49.89; H, 4.86; N, 18.86.

EXAMPLE 9

5

1-(2-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino) ethyl)-3-(3-(pyrrolidin-1-yl)propyl)thiourea



10

A solution of N-(3-aminopropyl)pyrrolidine (354 mg, 2.76 mmol) in THF (50 mL) was cooled to 0-5 °C in an ice-water bath under a nitrogen atmosphere and treated with 2-[N-(3,4-dichlorobenzyl)-N-(5-nitropyrid-2-yl)]aminoethyl isothiocyanate (1.19 g, 2.76 mmol) in THF (25 mL). The reaction mixture was allowed to warm to room temperature and was stirred overnight. Removal of the solvent under reduced pressure afforded an oil which solidified upon trituration with hexane-EtOAc. Recrystallization from EtOAc-hexane afforded 1.03 g (66%) of the title compound as a white solid.

20

mp 123-125 °C.

¹H NMR (90 MHz CDCl₃)d 1.77 (m, 6 H), 2.45 (m, 6 H), 3.50 (m, 6H), 4.68 (s, 2 H, ArH), 6.50 (d, 1 H), 7.00-7.55 (m, 6 H), 8.16 (d, J = 2.2 Hz, 1 H).

25

¹³C NMR (90 MHz CDCl₃)d 23.62, 28.17, 43.07, 47.89, 51.74, 107.59, 108.08, 126.33, 128.83, 130.94, 138.47, 140.26, 148.55, 156.84, 183.0.

Anal.


Calcd for $C_{22}H_{28}BrCl_2N_5S$: C, 48.44; H, 5.18; N, 12.84.

Found: C, 48.40; H, 5.26; N, 12.77.

5

EXAMPLE 10

10 1-(2-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino) ethyl)-3-(3-dimethylaminopropyl)thiourea



15 A solution of N-1-(5-bromopyrid-2-yl)-1-(3,4-dichlorobenzyl)ethane-1,2-diamine (1.00 g, 2.67 mmol) in THF (25 mL) was cooled to 0-5 °C under a nitrogen atmosphere and treated dropwise with a solution of 3-(dimethylamino)propyl isothiocyanate (385 mg, 2.67 mmol) in THF (15 mL). After stirring overnight at room temperature, the solvent was removed under reduced pressure to afford an oil. Flash chromatography on silica gel using a solvent system of EtOAc 85: CH₃OH 15: concentrated NH₄OH 1
20 gave 900 mg (65%) of the title compound as a white foam.


¹H NMR (90 MHz CDCl₃)d 1.70 (9m, 2 H), 1.95-2.45 (m, including a singlet at 2.23 N(CH₃)₂, 8 H), 2.50-3.95 (m, 6 H), 4.68 (s, 2 H, ArCH₂), 6.47 (d, J = 9 Hz, 1 H), 7.20 (m, 6 H), 7.55 (d, J = 2.2 Hz, 1 H), 8.18 (d, J = 2.5 Hz, 1 H).

25

¹³C NMR (90 MHz CDCl₃)d 26.32, 43.11, 44.85, 47.67, 51.52, 57.28, 107.97, 126.06, 128.55, 130.77, 131.26, 132.89, 138.09, 140.15, 148.33, 156.72, 182.46.

EXAMPLE 11

- 5 1-(3-(N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino)propyl)-3-(3-(imidazol-1-yl)propyl)thiourea dihydrobromide



10

Following the method for the synthesis of N-1-(5-bromopyrid-2-yl)ethane-1,2-diamine, 2-bromopyridine (20.0 g, 126.7 mmol), pyridine (12.7 g, 160.8 mmol), and 1,3-diaminopropane (47.4 g, 639 mmol) afforded a dark brown oil. Vacuum distillation
15 gave 9.19 g (48 %) of a N-1-(pyrid-yl)propane-1,3-diamine as a light yellow oil.

bp 111-114 °C (0.65 mm).

¹H NMR (90 MHz CDCl₃)d 1.28 (br s, 2 H, NH₂), 1.75 (m, 2 H), 2.84 (t, 2 H), 3.35 (m,
20 2 H), 5.00 (br s, 2 H, NH), 6.50 (m, 2 H), 7.40 (ddd, 1 H), 8.07 (m, 1 H).

¹³C NMR (90 MHz CDCl₃)d 32.93, 39.92 (2X), 106.77, 112.30, 137.17, 148.00, 159.00.

- 25 Following the procedure described for the synthesis of N-1-(5-bromopyrid-2-yl)-1-(3,4-dichlorobenzyl)ethane-1,2-diamine, N-1-(pyrid-yl)propane-1,3-diamine (5.00 g, 33.1 mmol), sodium hydride as a 60 % mineral oil dispersion (1.39 g, 34.8 mmol),

and 4-bromobenzyl bromide (8.27 g, 33.1 mmol) in DMSO (50 mL) gave a yellow oil. Flash chromatography on silica gel using CH₂Cl₂ 90: CH₃OH 5: Et₃N 5 as the solvent system afforded 2.28 g (22 %) of N-1-(4-bromobenzyl)-1-(pyrid-2-yl)propane-1,3-diamine as a light yellow oil.

5

¹H NMR (90 MHz CDCl₃)d 1.75 (m, 4 H, CH₂ and NH₂), 2.72 (t, 2 H), 3.59 (t, 2 H, NCH₂), 4.72 (s, 2 H, ArCH₂), 6.38-7.00 (m, 7 H, ArH), 8.16 (d, 1 H, pyridine H-6).

¹³C NMR (90 MHz CDCl₃)d 31.21, 39.50, 45.73, 50.98, 105.81, 112.04, 120.60,

10 128.62, 131.65, 137.34, 137.93, 148.07, 158.20.

A solution of N-1-(4-bromobenzyl)-1-(pyrid-2-yl)propane-1,3-diamine (616 mg, 1.92 mmol) in THF (15 mL) was treated dropwise with 3-(imidazol-1-yl)propyl

15 isothiocyanate (323 mg, 1.92 mmol) in THF (10 mL) under a nitrogen atmosphere.

After stirring overnight at room temperature, the solid was filtered. Evaporation of the filtrate under reduced pressure gave a yellow oil which was dissolved in methanol and acidified with methanolic hydrogen bromide. Addition of diethyl ether afforded a cloudy solution which produced a light tan solid upon standing in the refrigerator.

20 The solid was filtered and dried to yield 0.94 g (75%) of the title compound.

Recrystallization from absolute ethanol-diethyl ether afforded an analytical sample.

mp 199-201 °C.

25 ¹H NMR (DMSO-d₆) d 1.55-2.25 (m, 4 H, CH₂), 3.20-3.90 (m, 6 H, CH₂), 4.26 (t, 2 H, CH₂-imidazole), 7.00 (t, 1 H), 7.26 (d, J = 8.3 Hz, 2 H, 2,6 H of C₆H₄-4-Br), 7.57 (d, J = 8.3 Hz, 3,5 H of C₆H₄-4-Br), 7.86 (m, 9 H).

¹³C NMR (DMSO-d₆) d 25.57, 29.09, 37.87, 39.98, 46.10, 47.40, 51.57, 111.76,

30 112.20, 121.78, 131.37, 134.73, 135.11, 137.44, 143.40, 151.27, 181.66.


Anal.

Calcd for $C_{22}H_{26}Br_3N_6S$: C, 40.69; H, 4.51; N, 12.95.

Found: C, 39.96; H, 4.52; N, 12.65.

5 EXAMPLE 12

1-(3-(N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino)propyl)-3-(4-(N-(pyridin-2-yl)amino)propyl)thiourea



Following the method for the synthesis of N-1-(5-bromopyrid-2-yl)ethane-1,2-diamine, 2-bromopyridine (20.0 g, 126.7 mmol), pyridine (12.7 g, 160.8 mmol), and 1,3-diaminopropane (47.4 g, 639 mmol) afforded a dark brown oil. Vacuum distillation gave 9.19 g (48 %) of a N-1-(pyrid-yl)propane-1,3-diamine as a light yellow oil.

bp 111-114 °C (0.65 mm).

20 ^1H NMR (90 MHz CDCl_3)d 1.28 (br s, 2 H, NH_2), 1.75 (m, 2 H), 2.84 (t, 2 H), 3.35 (m, 2 H), 5.00 (br s, 2 H, NH), 6.50 (m, 2 H), 7.40 (ddd, 1 H), 8.07 (m, 1 H).

^{13}C NMR (90 MHz CDCl_3)d 32.93, 39.92 (2X), 106.77, 112.30, 137.17, 148.00, 159.00.

25

A solution of N-1-(pyridyl)propane-1,3-diamine (419 mg, 2.76 mmol) in THF (25 mL) was cooled to 0-5 °C under a nitrogen atmosphere and treated dropwise with 3-[N-(4-

bromobenzyl)-N-(pyrid-2-yl)]aminopropyl isothiocyanate (1.00 g, 2.76 mmol) in THF (10mL). After stirring overnight at room temperature, the solvent was removed under reduced pressure to afford an oil. The oil was flash chromatographed on silica gel using a solvent system of CH₂Cl₂ 90: CH₃OH 5: Et₃N 5 to yield 9, 50 mL fractions.

- 5 Fractions 3-9 were combined and the solvents were removed under reduced pressure to give 1.31 g (92%) of the title compound as an oil (R_f = 0.5).

¹H NMR (90 MHz CDCl₃)d 1.82-2.40 m, 7 H), 3.58 (m, 5 H), 4.57 (s, 2 H, ArCH₂), 4.75 (br m, NH), 6.35-8.14 (m, 14 H).

10

¹³C NMR (90 MHz CDCl₃)d 27.14, 29.53, 38.63, 41.17, 45.34, 51.30, 106.40, 108.29, 112.52, 112.85, 120.86, 128.18, 131.81, 136.68, 137.39, 137.77, 147.63, 158.73, 181.05.

- 15 MS (CI, CH₄) m/z 513 (M⁺).

Anal.

Calcd for C₂₄H₂₉BrN₆S: C, 56.14; H, 5.69; N, 16.37.

Found: C, 56.10; H, 5.73; N, 16.34.


20

EXAMPLE 13

1-(3-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino) propyl)-3-(3-(imidazol-1-yl)propyl)thiourea

25

58



Following the method described for the synthesis of N-1-(5-bromopyrid-2-yl)-1-(3,4-dichlorobenzyl)ethane-1,2-diamine, N-1-(5-bromopyrid-yl)propane-1,3-diamine (5.00 g, 21.7 mmol), a 60% mineral oil suspension of sodium hydride (0.914 g, 22.9 mmol), and 3,4-dichlorobenzyl chloride (4.25 g, 21.7 mmol) in DMSO (45 mL) gave an oil. Flash chromatography on silica gel using CH₂Cl₂ 90: CH₃OH 5:Et₃N 5 as the solvent yielded 4.92 g (58%) of the N-1-(5-bromopyrid-2-yl)-1-(3,4-dichlorobenzyl)propane-1,3-diamine as an oil.

¹H NMR (90 MHz CDCl₃)d 1.44 (s, 2 H, NH₂), 1.80 (m, 2 H), 2.73 (t, 2 H), 3.56 (t, 2 H), 4.66 (s, 2 H, ArCH₂), 6.37 (d, J = 9 Hz, 1 H, pyridine H-3), 7.31 (m, 4 H), 8.15 (d, J = 2.5 Hz, 1 H, pyridine H-6).

¹³C NMR (90 MHz CDCl₃)d 30.93, 39.44, 46.21, 50.71, 106.67, 107.16, 126.23, 128.72, 130.51, 130.89, 132.62, 138.90, 139.66, 148.55, 156.46.

A solution of N-1-(5-bromopyrid-2-yl)-1-(3,4-dichloro benzyl)propane-1,3-diamine (1.00 g, 2.57 mmol) in THF was cooled to 0-5 °C under a nitrogen atmosphere and treated dropwise with 3-(1-imidazolyl)propyl isothiocyanate (432 mg, 2.57 mmol) in THF (15 mL). The reaction mixture was allowed to warm to room temperature and was stirred overnight. Removal of the solvent under reduced pressure afforded a semisolid. Trituration with diethyl ether-petroleum ether gave a solid which was

recrystallized from ethyl acetate-diethyl ether to yield 450 mg (31%) of the title compound.

mp 94-97 °C (decomposition).

5

¹H NMR (90 MHz CDCl₃) δ 1.60-2.35 (m, 4 H), 3.54 (m, 5 H), 4.05 (t, 2 H, CH₂-imidazole) 4.57 (s, 2 H, ArCH₂), 6.28 (d, J = 9 Hz, 1 H), 6.99 (d, J = 4.4 Hz, 1 H), 7.19 (m, 9 H).

10 ¹³C NMR (90 MHz CDCl₃) δ 27.03, 30.91, 41.01, 41.50, 44.59, 45.94, 51.03, 107.05, 107.64, 119.18, 125.90, 128.39, 129.21, 130.78, 131.21, 132.89, 136.95, 137.98, 140.04, 148.33, 156.62, 182.62.


Anal.

15 Calcd for C₂₂H₂₅BrCl₂N₆S: C, 47.49; H, 4.53; N, 15.11.

Found: C, 47.23; H, 4.59; N, 14.98.

EXAMPLE 14

20 1-(3-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino) propyl)-3-(4-(N-(pyridin-2-yl)amino)propyl)thiourea



25

Using the general method, DCC (1.94 g, 9.35 mmol), carbon disulfide (7.62 g, 100 mmol), and N-1-(5-bromopyrid-2-yl)-1-(3,4-dichlorobenzyl)propane-1,3-diamine (3.64

g, 9.35 mmol) in THF (45 mL) gave an oil. Purification by flash chromatography on silica gel using hexane 70: EtOAc 30:Et₃N 1 as the solvent afforded 3.19 g (79%) of 3-[N-(5-bromopyrid-2-yl)-N-(3,4-dichlorobenzyl)]aminopropyl isothiocyanate as an oil.

5 ¹H NMR (90 MHz CDCl₃) δ 2.06 (m, 2 H), 3.62 (m, 4 H), 4.66 (s, 2 H, ArCH₂), 6.40 (m, 1 H), 7.35 (m, 4 H), 8.22 (m, 1 H).

¹³C NMR δ 28.06, 42.91, 46.10, 51.41, 107.21, 107.43, 126.17, 128.72, 130.72, 131.26, 138.31, 139.93, 148.76, 156.13.

10

MS (CI, CH₄) 432 M⁺.

Anal.

Calcd for C₁₈H₁₄BrCl₂N₃S: C, 44.56; H, 3.28; N, 9.75.

15 Found: C, 44.39; H, 3.42; N, 9.79.

A solution of N-1-(4-bromobenzyl)-1-(pyrid-2-yl)propane-1,3-diamine (352 mg, 2.32 mmol) in THF (30 mL) was cooled to 0-5 °C under nitrogen and treated dropwise with 3-[N-(5-bromopyrid-2-yl)-N-(3,4-dichlorobenzyl)]aminopropyl isothiocyanate (1.00 g, 2.32 mmol) in THF (20 mL). After stirring at room temperature overnight, the solvent was removed under reduced pressure to afford an oil. Flash chromatography on silica gel using a solvent system of CH₂Cl₂ 98: CH₃OH 1: Et₃N 1 gave the title compound as an oil which solidified upon trituration with hexane. Recrystallization from ethyl acetate-hexane gave a hygroscopic solid.

25

mp 88 °C (decomposition);

¹H NMR (90 MHz CDCl₃) δ 0.90-2.10 (m, 4 H), 3.50 (m, 8 H), 4.57 (s, 2 H, ArCH₂), 4.90 (br s, 1 H, NH), 6.30 (d, J = 9.3 Hz, 1 H, pyridine H-3), 6.45-8.18 (m, 11 H, ArH and NHC=SNH);

30

^{13}C NMR (90 MHz CDCl_3) δ 27.09, 29.64, 38.63, 41.34, 41.45, 46.05, 51.14, 107.16, 107.65, 108.57, 112.90, 125.99, 128.51, 130.78, 131.21, 132.89, 137.55, 138.15, 140.10, 147.30, 148.50, 156.62, 158.79, 181.43;

5 MS (Cl , CH_4) m/z 583 (M^+).


Anal.

Calcd for $\text{C}_{24}\text{H}_{27}\text{BrCl}_2\text{N}_6\text{S}$: C, 49.50; H, 4.67; N, 14.43. Found: C, 49.28; H, 4.57; N, 14.21.

10

EXAMPLE 15

15 1-(3-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino) propyl)-3-(3-(1H-imidazol-4-yl)propyl)thiourea



20 A suspension of 3-[1-(triphenylmethyl)imidazol-4-yl] propylamine (1.32 g, 3.60 mmol) in THF (50 mL) was treated dropwise with of 3-[N-(5-bromopyrid-2-yl)-N-(3,4-dichloro benzyl)]aminopropyl isothiocyanate (1.55 g, 3.60 mmol) in THF (25 mL) at 0-5 °C under a nitrogen atmosphere. The reaction mixture was allowed to warm to room temperature and was stirred overnight. Removal of the solvent under reduced
25 pressure afforded an oil. Flash chromatography on silica gel using a solvent system of EtOAc 92: CH_3OH 4: Et_3N 4 gave 2.10 g (73%) of the trityl-protected thiourea. The

oil was suspended in 2 N HCl (50 mL) and was refluxed for 7 h. The precipitated triphenylmethanol was filtered, and the aqueous acid was evaporated under reduced pressure to yield a foam. The hygroscopic hydrochloride was converted to the free base with 1 N NaOH, and the aqueous layer was extracted with EtOAc (3 x 75 mL).

5 The combined extracts were washed with water (2 x 50 mL), dried (Na_2SO_4), filtered, and evaporated to afford 600 mg of a foam. Purification by flash chromatography on silica gel using EtOAc 85: CH_3OH 15: concentrated NH_4OH 1 as the solvent system gave 533 mg (27%) of the title compound as a solid foam.

10 ^1H NMR (90 MHz CDCl_3)d 2.05 (m, 4 H), 2.70 (m, 2 H), 3.59 (m, 6 H), 4.59 (s, 2 H, ArCH_2), 6.30 (d, $J = 9.3$ Hz, 1 H), 6.50-8.11 (m, 9 H);

^{13}C NMR (90 MHz CDCl_3)d 23.73, 27.03, 28.82, 41.88, 43.29, 46.10, 106.99, 107.70, 115.93, 126.01, 128.50, 130.72, 131.10, 132.78, 134.41, 137.39, 138.20, 140.04,

15 148.33, 156.56, 181.38.

Anal.


Calcd. for $\text{C}_{22}\text{H}_{25}\text{BrCl}_2\text{N}_6\text{S}$: C, 47.49; H, 4.54; N, 15.11.

Found: C, 47.48; H, 4.48; N, 14.96.

20

EXAMPLE 16

1-(3-(N-(5-Bromopyridin-2-yl)-N-((naphth-1-yl)methyl)amino)propyl)-3-(3-(1H-
25 imidazol-4-yl)propyl)thiourea



According to the method for the synthesis of N-1-(5-bromopyrid-2-yl)ethane-1,2-diamine, 2,5-dibromopyridine (4.40 g, 18.6 mmol), pyridine (1.86 g, 23.6 mmol), and 1,3-diaminopropane (25 mL) yielded an oil. Vacuum distillation afforded 2.69 g (63%) of N-1-(5-bromopyrid-yl)propane-1,3-diamine as an oil.

bp 135-139 °C (0.1 mm);

¹H NMR (90 MHz CDCl₃)d 1.52 (br s, 2 H, NH₂), 1.72 (m, 2 H), 2.89 (t, 2 H), 3.36 (m, 2 H), 5.30 (br s, 1 H, NH), 6.29 (d, J = 9 Hz, 1 H, pyridine H-3), 7.44 (dd, J = 2.4 Hz, J = 8.8 Hz, 1 H, pyridine H-4), 8.09 (d, J = 2.4 Hz, 1 H, pyridine H-6);

¹³C NMR (90 MHz CDCl₃)d 32.61, 39.98, 40.25, 106.45, 108.29, 139.50, 148.49, 157.48.

N-[1-(5-bromopyrid-2-yl)-1-(naphthal-1-yl)methyl]propane-1,3-diamine (3e). Using the method described for the synthesis of N-1-(5-bromopyrid-2-yl)-1-(3,4-dichlorobenzyl)ethane-1,2-diamine, N-1-(5-bromopyrid-yl)propane-1,3-diamine (8.71 g, 37.9 mmol), a 60 % mineral oil dispersion of sodium hydride (1.67 g, 41.6 mmol), and 1-(bromomethyl)naphthalene (9.21 g, 41.6 mmol) in DMSO (60 mL) gave an oil. Flash chromatography on silica gel using CH₂Cl₂ 50: CH₃OH 50: concentrated ammonium hydroxide 1 afforded 5.10 g (35 %) of N-[1-(5-bromopyrid-2-yl)-1-(naphthal-1-yl)methyl]propane-1,3-diamine as an oil.

¹H NMR (90 MHz CDCl₃)d 1.43 (br s, 2 H, NH₂), 1.75 (m, 2 H), 3.67 (t, 2 H), 5.12 (s, 2 H, CH₂-a-naphthalylmethyl) 6.31 (d, J = 9 Hz, 1 H, pyridine H-3), 7.15-8.05 (m, 8 H, ArH), 8.20 (d, J = 2.4 Hz, 1 H, pyridine H-6);

5

¹³C NMR (90 MHz CDCl₃)d 31.31, 39.55, 45.72, 49.62, 106.29, 107.54, 122.76, 123.84, 125.47, 125.85, 126.23, 127.74, 128.94, 131.32, 132.24, 133.92, 139.55, 148.55, 156.94.

10

Following the procedure described for the preparation of 2-[N-(5-bromopyrid-2-yl)-N-(3,4-dichloro benzyl)]aminoethyl isothiocyanate, DCC (2.32 g, 10.8 mmol), carbon disulfide (8.80 g, 115 mmol) and N-[1-(5-bromopyrid-2-yl)-1-(naphthal-1-yl)methyl]propane-1,3-diamine (4.00 g, 10.8 mmol) in THF (140 mL) afforded an oil.

15 Flash chromatography on silica gel using a solvent system of hexane 50: CH₂Cl₂ 50: Et₃N 1 gave 2.70 g (84 %) of 3-[N-(5-bromopyrid-2-yl)-N-(naphthal-1-yl)methyl]aminopropyl isothiocyanate as a colorless oil.

¹H NMR (90 MHz CDCl₃)d 2.00 (m, 2 H, NCH₂CH₂CH₂N=C), 3.54 (t, 2 H), 3.74 (t, 2H),
20 5.11 (s, 2 H, ArCH₂), 6.30 (d, J = 9 Hz, 1 H, pyridine H-3), 7.15-8.02 (m, 8 H, ArH), 8.25 (d, J = 2.4 Hz, 1 H, pyridine H-6);

¹³C NMR d 28.28, 43.01, 45.77, 50.32, 106.99, 107.59, 122.65, 123.89, 125.41, 125.90, 126.39, 127.96, 128.93, 139.71, 148.60, 156.62.

25

A solution of 3-[1-(triphenylmethyl)imidazol-4-yl]propylamine (1.24 g, 3.38 mmol) was dissolved in THF (20 mL) and treated dropwise with a solution of 3-[N-(5-bromopyrid-2-yl)-N-(naphthal-1-yl)methyl] aminopropyl isothiocyanate (1.40 g, 3.38 mmol) in THF (20 mL) at 0-5 °C under a nitrogen atmosphere. The reaction mixture was allowed to
30 warm to room temperature and was stirred overnight. The solvent was evaporated under reduced pressure to yield an oil which was purified by flash chromatography on

silica gel using a solvent system of EtOAc 92: CH₃OH 4: Et₃N 4. Fractions homogeneous on TLC were combined and evaporated to give 2.63 g of the trityl-protected thiourea. The oil was suspended in 1 N HCl (60 mL) and refluxed for 1.5 h. The precipitate was filtered, and the filtrate was extracted with diethyl ether (2 x 100 mL). The aqueous layer was basified with 6 N NaOH and extracted with ethyl acetate (3 x 100 mL). The combined ethyl acetate extracts were washed with water (2 x 50 mL), dried (Na₂SO₄), filtered, and evaporated to yield an oil. Flash chromatography on silica gel using an eluent of CH₂Cl₂ 90: CH₃OH 10: concentrated NH₄OH 1 afforded 1.10 g (61 %) of the title compound as a foam.

¹H NMR (90 MHz CDCl₃)d 1.88 (m, 4 H), 2.65 (m, 2 H), 3.30-3.80 (m, 6 H), 5.02 (s, 2 H, 1-naphthyl-CH₂), 6.18-8.11 (m, 14 H, ArH and NHC=SNH);

¹³C (90 MHz CDCl₃)d 24.06, 27.19, 29.38, 42.20, 43.75, 50.94, 108.44, 115.63, 122.50, 123.44, 125.31, 125.94, 126.56, 128.13, 129.38, 131.56, 134.75, 135.00, 138.75, 140.63, 148.44, 157.81, 181.56.

Anal.


Calcd for C₂₆H₂₉BrN₆S: C, 58.09; H, 5.45; N, 15.64.

Found: C, 57.72; H, 5.62; N, 15.61.

EXAMPLE 17

1-(4-Aminobutyl)-3-(3-(N-(5-bromopyridin-2-yl)-N-((naphth-1-yl)methyl)amino)propyl)thiourea

66




A solution of (4-phthalimido butyl)amine hydrochloride (688 mg, 2.7 mmol) and
5 triethylamine (547 mg, 5.4 mmol) in THF (25 mL) was stirred for 2 h at room
temperature. The reaction mixture was treated dropwise with a solution of 3-[N-(5-
bromopyrid-2-yl)-N-(naphthal-1-yl)methyl] aminopropyl isothiocyanate (1114 mg, 2.7
mmol) in THF (20 mL), and the mixture was stirred overnight under nitrogen. The
precipitated triethylamine hydrochloride was filtered, and the filtrate was evaporated
10 under reduced pressure to afford an oil. Purification by flash chromatography on
silica gel using a solvent system of CH₂Cl₂ 100: CH₃OH 2: concentrated NH₄OH 1
gave 1.08 g of a yellow foam. The foam was suspended in a mixture of ethanol (20
mL) and 85% hydrazine hydrate (641mg, 12.7 mmol), and the mixture was refluxed
for 5 h. The mixture was filtered to remove the precipitated phthalhydrazide, and the
15 solvent was removed under reduced pressure to yield an oily residue. The oil was
dissolved in CH₂Cl₂ (75 mL), washed with water (3 x 50 mL), separated, dried
(Na₂SO₄), filtered, and evaporated to yield 700 mg of the amine as a light yellow
foam. Flash chromatography on silica gel using EtOAc 50: CH₃OH 50: concentrated
NH₄OH 1 as the solvent yielded 650 (48%) of the title compound as a white foam.

20 ¹H NMR (90 MHz CDCl₃)d 1.70 (m, 10 H), 2.79 (m, 2 H), 3.70 (m, 6 H), 5.06 (s, 2 H,
ArCH₂), 6.29 (d, 9 Hz, 1 H), 6.70–8.20 (m, 11 H);

¹³C NMR (90 MHz CDCl₃)d 26.32, 27.18, 30.27, 41.43, 41.59, 43.71, 45.39, 49.83,
25 106.66, 108.34, 122.37, 123.07, 125.45, 126.00, 126.43, 127.95, 129.03, 130.82,
131.03, 133.86, 140.08, 147.99, 157.47, 181.03.

EXAMPLE 18

- 5 1-(4-Aminobutyl)-3-[3-[N-(5-bromopyrid-2-yl)]-N-(3,4-dichlorobenzyl)]aminopropyl]thiourea



10

- A suspension of (4-phthalimidobutyl)amine hydrochloride (1.50 g, 5.89 mmol) and triethylamine (1.49 g, 14.7 mmol) was stirred under nitrogen for 3 h at room temperature, and a solution of 3-[N-(5-bromopyrid-2-yl)]-N-(3,4-dichlorobenzyl)]aminopropyl isothiocyanate (2.54 g, 5.89 mmol) in THF (50 mL) was added dropwise. After stirring overnight, the precipitate was filtered and the filtrate was evaporated under reduced pressure to yield an oil. Flash chromatography on silica gel using CH₂Cl₂ 100: CH₃OH 1:concentrated ammonium hydroxide 1.5 as the solvent afforded 2.06 g of the intermediate phthalimide as an oil. The oil was dissolved in a mixture of 85% hydrazine hydrate (635 mg, 12.7 mmol) and absolute ethanol (75 mL) and refluxed for 8 h. The reaction mixture was cooled, filtered, and evaporated to yield an oil. Absolute ethanol (25 mL) was added and the solution was concentrated under reduced pressure. The resulting residue was partitioned between diethyl ether (200 mL) and water (50 mL), and the diethyl ether phase was separated, dried (Na₂SO₄), filtered, and evaporated under reduced pressure. Flash chromatography on silica gel using EtOAc 50: CH₃OH 50: concentrated NH₄OH 1.2 afforded 1.15 g (70%) the title compound as a colorless oil.
- 15
- 20
- 25

¹H NMR (90 MHz CDCl₃) δ 1.66 (m, 6 H, CH₂ and NH₂), 2.80 (t, 2 H), 3.59 (m, 6 H), 4.62 (s, 2 H, ArCH₂), 6.35 (d, J = 9 Hz, 1 H, pyridine H-3), 6.99-7.56 (m, 6 H, ArH and NHC=SNH), 8.18 (d, J = 2.4 Hz, 1 H, pyridine H-6)

5

¹³C NMR δ 26.33, 27.09, 30.28, 41.44, 41.61, 43.83, 50.98, 107.75, 125.90, 128.39, 130.78, 137.87, 140.15, 148.28, 156.78, 181.11.

Anal.


10 Calcd. for C₂₀H₂₆BrCl₂N₅S: C, 42.26; H, 5.05; N, 13.49.

Found: C, 46.09; H, 5.10; N, 12.90.

EXAMPLE 19

15

1-(3-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino) propyl)-3-(3-(pyrrolidin-1-yl)propyl)thiourea



20

A solution of N-(3-aminopropyl)pyrrolidine (354 mg, 2.76 mmol) in THF (50 mL) was cooled to 0-5 °C under a nitrogen atmosphere and treated dropwise with a solution of 3-[N-(5-bromopyrid-2-yl)-N-(3,4-dichlorobenzyl)]aminopropyl isothiocyanate (1.19 g, 2.76 mmol) in THF (25 mL). The reaction mixture was allowed to warm to room temperature and was stirred overnight. The solvent was removed under reduced pressure to afford an oil which solidified upon trituration with hexane-ethyl acetate.

25

Recrystallization from ethyl acetate-hexane gave 1.03 g (66%) of the title compound as a white solid.

mp 122-124 °C;

5

¹H NMR (90 MHz CDCl₃) δ 1.73 (m, 8 H), 2.57 (m, 6 H), 3.60 (m, 6 H), 4.63 (s, 2 H, ArCH₂), 6.33 (d, J = 9 Hz, 1 H, pyridine H-3), 7.00–7.53 (m, 6 H, ArH and NHC=SNH), 8.18 (d, J = 2.4 Hz, 1 H, pyridine H-6);

10 ¹³C NMR (90 MHz CDCl₃)d 23.46, 27.14, 41.99, 46.16, 51.09, 53.36, 53.69, 107.05, 107.48, 126.12, 128.61, 130.72, 132.72, 132.84, 138.31, 139.99, 148.55, 156.51, 182.13.


Anal.

15 Calcd. for $C_{23}H_{30}BrCl_2N_5S$: C, 49.39; H, 5.41; N, 12.52.
Found: C, 49.14; H, 5.44; N, 12.45

EXAMPLE 20

20

1-(3-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino) propyl)-3-(2-(pyrid-2-yl)ethyl)thiourea



25

A solution of 2-(2-aminoethyl)pyridine (0.33 g, 2.71 mmol) in THF (50 mL) was cooled to 0-5 °C under a nitrogen atmosphere and treated with a solution of 3-[N-(5-

bromopyrid-2-yl)-N-(3,4-dichlorobenzyl)]aminopropyl isothiocyanate (1.17 g, 2.71 mmol) in THF (25 mL). The reaction mixture was allowed to warm to room temperature and was stirred overnight. Removal of the solvent under reduced pressure afforded an oil which was purified by flash chromatography on silica gel using EtOAc 96: CH₃OH 4: concentrated NH₄OH 1 as the solvent system. Fractions homogeneous by TLC were combined and evaporated to yield 1.11 g (74%) of the title compound as a foam.

¹H NMR (90 MHz CDCl₃) δ 1.78 (m, 2 H), 3.00 (t, 2 H), 3.69 (m, 6 H), 4.59 (s, 2 H, ArH), 6.30 (d, J = 9 Hz, 1 H, pyridine H-3), 6.88-8.49 (m, 11 H, ArH and NHC=SNH);

¹³C NMR (90 MHz CDCl₃) δ 26.82, 36.30, 41.34, 43.34, 45.89, 50.93, 107.05, 107.59, 121.84, 123.63, 125.91, 128.40, 130.67, 131.11, 132.79, 136.96, 137.99, 139.99, 148.50, 148.93, 156.57, 159.06, 181.11.


Anal.

Calcd. for C₂₃H₂₄BrCl₂N₅S: C, 49.93; H, 4.37; N, 12.66.

Found: C, 49.81; H, 4.43; N, 12.42.

EXAMPLE 21

1-(4-(N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino)butyl)-3-(3-(imidazol-1-yl)propyl)thiourea



Following the general method described for N-1-(5-bromopyrid-2-yl)ethane-1,2-diamine, 2-bromopyridine (20.0 g, 126.7 mmol), 1,4-diaminobutane (56.3 g, 639 mmol), and pyridine (12.7 g, 160.8 mmol) gave 11.5 g (55%) of N-1-(pyrid-2-yl)butane-1,4-diamine as a light yellow oil.

5

bp 103-105 °C (0.05 mm);

¹H NMR (90 MHz CDCl₃) δ 1.56 (br s, 2 H, NH₂), 1.61 (m, 4 H), 2.73 (t, 2 H), 3.25 (m, 2 H), 4.73 (br s, 1 H, NH), 6.43 (m, 2 H), 7.40 (ddd, 1 H), 8.08 (m, 1 H);

10

¹³C NMR (90 MHz CDCl₃) δ 27.03, 31.25, 41.98, 42.09, 106.56, 112.57, 137.27, 148.22, 159.00.

15 In a similar manner as described for the preparation of N-1-(5-bromopyrid-2-yl)-1-(3,4-dichlorobenzyl)ethane-1,2-diamine, a 60 % dispersion of sodium hydride (1.27 g, 31.8 mmol), N-1-(pyrid-2-yl)butane-1,4-diamine (10.1 g, 30.3 mmol), and 4-bromobenzyl bromide (7.57 g, 30.3 mmol) in DMSO (60 mL) gave an oil. Flash chromatography on silica gel using CH₂Cl₂ 90: CH₃OH 5: Et₃N 5 yielded 4.29 g (57%)
20 of N-1-(4-bromobenzyl)-1-(pyrid-2-yl)butane-1,4-diamine as a thick oil.

¹H NMR (90 MHz CDCl₃) δ 1.45 (m, 4 H, CH₂ and NH₂), 2.65 (t, 2 H), 3.45 (t, 2 H), 4.70 (s, 2 H, ArCH₂), 6.95 (m, 2 H), 7.25 (m, 5 H), 8.15 (m, 1 H);

25 ¹³C NMR (90 MHz CDCl₃) δ 24.66, 31.05, 41.94, 48.39, 50.99, 105.65, 111.88, 113.01, 120.49, 128.67, 130.24, 130.24, 130.73, 131.49, 137.23, 138.15, 148.07, 157.93.

30 A solution of N-1-(4-bromobenzyl)-1-(pyrid-2-yl)butane-1,4-diamine (1.11 g, 3.34 mmol) in THF (30 mL) was treated dropwise with a solution of 3-(imidazol-1-yl)propyl

isothiocyanate (559 mg, 3.34 mmol) in THF (10 mL). After stirring overnight at room temperature under nitrogen, the solvent was removed under reduced pressure to afford an oil. The oil was dissolved in absolute ethanol and acidified with ethanolic hydrogen chloride. Addition of diethyl ether afforded a very hygroscopic solid. The

- 5 solvents were removed under reduced pressure, and the residue was partitioned between 10% NaOH (100 mL) and methylene chloride (50 mL). The basic layer was extracted with methylene chloride (2 x 50 mL), and the combined organic extracts were washed with water (2 x 50 mL), dried (Na₂SO₄), filtered, and evaporated. The resulting oil was triturated with diethyl ether to yield 950 mg (57%) of a tan solid.
- 10 Recrystallization from ethyl acetate-diethyl ether afforded 691 mg (41%) the title compound.

mp 122-124 °C;

- 15 ¹H NMR (90 MHz CDCl₃)d 1.63 (m, 4 H), 2.07 (m, 2 H), 3.55 (m, 6 H), 4.01 (t, J = 7.4 Hz, 2 H, CH₂-imidazole), 4.66 (s, 2 H, ArCH₂), 6.36-8.18 (m, 13 H, ArH and NHC=SNH);

- ¹³C NMR (90 MHz CDCl₃)d 25.02, 26.16, 30.61, 41.28, 44.09, 44.16, 48.05, 51.19,
20 106.02, 112.14, 119.23, 120.64, 128.50, 129.09, 131.64, 136.95, 137.49, 147.84, 157.97, 182.89.


Anal.

Calcd for C₂₃H₂₉BrN₆S: C, 54.48; H, 5.84; N, 16.76.

- 25 Found: C, 55.04; H, 5.90; N, 16.67.

EXAMPLE 22

- 30 1-(4-(N-(3,4-Dichlorobenzyl)-N-(pyridin-2-yl)amino)butyl)-3-(3-(imidazol-1-yl)propyl)thiourea



- 5 Following the general method, a 60 % mineral oil dispersion of sodium hydride (613 mg, 15.3 mmol), N-1-(pyrid-2-yl) butane-1,4-diamine (2.41 g, 14.6 mmol), and 3,4-dichloro benzyl bromide (3.50 g, 14.6 mmol) gave an oil. Purification by flash chromatography on silica gel using a solvent system of CH₂Cl₂ 50: CH₃OH 50: concentrated NH₄OH 1 afforded 0.950 g (20%) of a light green oil.
- 10 ¹H NMR (90 MHz CDCl₃) δ 1.52 (m, 4 H), 2.02 (br s, 2 H, NH₂), 2.70 (t, 2 H), 3.43 (t, 2 H), 4.71 (s, 2 H, ArCH₂), 6.50 (m, 2 H), 7.00-7.52 (m, 4 H), 8.16 (m, 1 H).
- 15 A solution of N-1-(3,4-dichlorobenzyl)-1-(pyrid-2-yl)butane-1,4-diamine (900 mg, 2.79 mmol) in THF (20 mL) was treated dropwise with 3-(imidazol-1-yl)propyl isothiocyanate (470 mg, 2.79 mmol) in THF (15 mL). After stirring overnight under nitrogen, the solvent was removed under reduced pressure. The resulting residue was flash chromatographed on silica gel using a solvent system of CH₂Cl₂ 100:
- 20 CH₃OH 10: concentrated ammonium hydroxide 1 to yield a yellow foam. The foam was triturated with methanol-water to yield a white solid. Recrystallization from methylene chloride-diethyl ether afforded 659 mg (48%) of the title compound as a white, crystalline solid.
- 25 mp 112-113.5 °C;

¹H NMR (90 MHz CDCl₃)d 1.60 (m, 4 H), 2.08 (m, 2 H), 3.50 (m, 6 H), 4.00 (t, 2 H), 4.63 (s, 2 H, ArCH₂), 7.20 (ArH and NHC=SNH);

¹³C NMR (90 MHz CDCl₃)d 24.97, 26.17, 30.61, 41.39, 44.10, 44.69, 48.22, 50.87,

5 106.02, 112.47, 126.23, 128.66, 129.21, 130.61, 137.71, 139.23, 147.95, 182.95.

Anal.

Calcd for C₂₃H₂₈Cl₂N₆S: C, 56.20; H, 5.75; N, 17.10.


Found: C, 56.03; H, 5.82; N, 16.99.

10

EXAMPLE 23

1-(4-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino) butyl)-3-(3-(imidazol-1-yl)propyl)thiourea

15



Using the method as described for the synthesis of N-1-(5-bromopyrid-2-yl)ethane-
20 1,2-diamine, 2,5-dibromopyridine (10.0 g, 42.2 mmol), 1,4-diaminobutane (52.6 g,
597 mmol), and dry pyridine (4.20 g, 53.2 mmol) gave a brown oil. Vacuum distillation
afforded 7.87 g (76 %) of N-1-(5-bromopyrid-2-yl)butane-1,4-diamine as a colorless
oil.

25 bp 165-170 °C (0.8 mm);

¹H NMR (90 MHz CDCl₃) δ 1.15-1.75 (m, 6 H), 2.72 (t, 2 H), 3.25 (br s, 2 H, NH₂), 4.75 (br s, 1 H, NH), 6.30 (d, J = 9 Hz, pyridine H-3), 7.47 (dd, J = 2.7 Hz, J = 9 Hz, 1 H, pyridine H-4), 8.10 (d, J = 2.4 Hz, pyridine H-6);

5 ¹³C NMR (90 MHz CDCl₃) δ 26.87, 31.09, 41.87, 42.20, 108.07, 139.66, 148.71.

Using a similar method as described for N-1-(5-bromopyrid-2-yl)-1-(3,4-dichlorobenzyl)ethane-1,2-diamine, a 60% mineral oil dispersion of sodium hydride
10 (1.20 g, 30.1 mmol), N-1-(5-bromopyrid-2-yl)butane-1,4-diamine (7.00 g, 28.7 mmol), and dichlorobenzyl chloride (5.62 g, 28.7 mmol) in DMSO (75 mL) gave an oil. Flash chromatography on silica gel using a solvent system of CH₂Cl₂ 50: CH₃OH 50: concentrated H₂O 1 yielded 2.32 g (20%) of N-1-(5-bromopyrid-2-yl)-1-(3,4-dichlorobenzyl)butane-1,4-diamine as an oil.

15

¹H NMR (90 MHz CDCl₃) δ 1.50 (m, 4 H, CH₂ and NH₂), 2.72 (t, 2 H), 3.45 (t, 2 H, NCH₂), 4.68 (s, 2 H, ArCH₂), 6.35 (d, J = 9 Hz, pyridine H-3), 7.00-7.55 (m, 4 H, ArH), 8.15 (d, J = 2.4 Hz, 1 H, pyridine H-6);

20 ¹³C NMR (90 MHz CDCl₃) δ 24.48, 30.93, 41.87, 48.81, 59.76, 106.61, 107.10, 126.28, 128.77, 130.45, 139.12, 139.60, 148.60, 156.29.

A solution of N-1-(5-bromopyrid-2-yl)-1-(3,4-dichlorobenzyl) butane-1,4-diamine (1.01
25 g, 2.48 mmol) in THF (20 mL) was treated dropwise with 3-(imidazol-1-yl)propyl isothiocyanate (431 mg, 2.48 mmol) in THF (15 mL). After stirring overnight at room temperature under nitrogen, the solvent was removed under reduced pressure. The resulting residue was triturated with hexane-diethyl ether to afford a solid.

Recrystallization from methylene chloride-diethyl ether gave 1.00 g (71%) the title
30 compound as white crystals.

mp 139-141 °C;

¹H NMR (90 MHz CDCl₃) δ 1.61 (m, 4 H), 2.07 (m, 2 H), 3.50 (m, 6 H), 4.00 (t, 2 H), 4.62 (s, 2 H, ArCH₂), 6.30 (d, J = 9 Hz, 1 H, pyridine H-3), 7.15 (m, 9 H), 8.12 (d, 1 H, pyridine H-6);

¹³C NMR (90 MHz CDCl₃) δ 24.70, 26.33, 30.44, 41.28, 43.87, 44.64, 48.43, 50.97, 106.77, 107.32, 119.23, 126.17, 128.61, 130.62, 130.99, 136.89, 138.74, 139.77, 148.54, 182.94.


Anal.

Calcd for C₂₃H₂₇BrCl₂N₆S: C, 48.42; H, 4.78; N, 14.74.

Found: C, 48.24; H, 4.89; N, 14.63.

EXAMPLE 24

1-(4-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino) butyl)-3-(3-(1H-imidazol-4-yl)propyl)thiourea



A mixture of DCC (858 mg, 4.16 mmol), carbon disulfide (1.85 g, 44.2 mmol), and N-1-(5-bromopyridin-2-yl)-1-(3,4-dichlorobenzyl) butane-1,4-diamine (1.68 g, 4.16 mmol) in THF (45 mL) afforded an oil. Purification by flash chromatography on silica gel

using a solvent system of hexane 80: EtOAc 20: Et₃N 1 gave 1.53 g (83%) of 4-[N-(5-bromopyrid-2-yl)-N-(3,4-dichlorobenzyl)] aminobutyl isothiocyanate as an oil.

¹H NMR (90 MHz CDCl₃)d 1.72 (m, 4 H), 3.54 (m, 4 H), 4.65 (s, 2 H, ArCH₂), 6.32 (d, J = 9 Hz, 1 H, pyridine H-3), 6.97-7.50 (m, 4 H), 8.16 (d, J = 2.4 Hz, 1 H, pyridine H-6);

¹³C NMR (90 MHz CDCl₃)d 24.32, 27.36, 44.80, 47.90, 51.62, 107.10, 126.18, 128.66, 130.56, 130.99, 132.67, 138.63, 139.71, 148.60, 156.18.

A suspension of 3-(1-triphenylmethyl-¹H-imidazol-4-yl)propyl amine (0.50 g, 1.51 mmol) in THF (20 mL) was treated dropwise with a solution of 4-[N-(5-bromopyrid-2-yl)-N-(3,4-dichlorobenzyl)]aminobutyl isothiocyanate (0.67 g, 1.51 mmol) in THF (10 mL) under a nitrogen atmosphere. After stirring overnight at room temperature, the solvent was removed under reduced pressure to afford an oil. Flash chromatography on silica gel using CH₂Cl₂ 100: CH₃OH 2.5:Et₃N 2.5 afforded 0.62 g (71%) of a colorless oil. The oil was suspended in a mixture of 2 N HCl (50 mL) and ethanol (10 mL) and refluxed for 10 h. After cooling the precipitated triphenylmethanol was filtered, and the filtrate was evaporated. The residue was suspended in 2 N NaOH (40 mL), and the aqueous phase was extracted with methylene chloride (3 x 50 mL). The combined methylene chloride extracts were washed with water (3 x 50 mL), dried (Na₂SO₄), filtered, and evaporated to give 107 mg (18%) of the title compound as a hygroscopic solid:


mp 63-67 °C;

¹H NMR (90 MHz CDCl₃)d 1.50-2.00 (m, 6 H), 2.60 (m, 2 H), 3.45 (br m, 6 H), 4.63 (s, 2 H, ArCH₂), 5.95-7.50 (m, 9 H, ArH and NHC=SNH), 8.13 (d, J = 2.4 Hz, 1 H, pyridine H-6);

^{13}C NMR (90 MHz CDCl_3) δ 23.51, 24.65, 28.88, 43.39, 44.37, 48.59, 50.87, 106.72, 107.37, 115.12, 126.23, 128.66, 130.56, 130.89, 132.62, 134.14, 138.20, 148.49, 156.29, 181.65.

5 **EXAMPLE 25**

1-(4-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino) butyl)-3-(2-(1H-imidazol-4-yl)ethyl)thiourea



A suspension of histamine (352 mg, 3.17 mmol) in THF (10 mL) was cooled to 0-5 °C and treated dropwise with 4-[N-(5-bromopyrid-2-yl)-N-(3,4-dichlorobenzyl)]aminobutyl isothiocyanate (1.41 g, 3.17 mmol) in THF (20 mL). After stirring overnight, the solvent was removed under reduced pressure to yield an oil which was purified by flash chromatography using a solvent system of EtOAc 85:CH₃OH 15: concentrated NH₄OH 1. Fractions homogeneous by TLC were combined and evaporated under reduced pressure to afford 1.59 g (90%) of the title compound as a white foam.


^1H NMR (90 MHz CDCl_3) δ 1.60 (m, 4 H), 2.80 (m, 2 H), 3.60 (m, 8 H), 4.63 (s, 2 H, ArCH_2), 6.37 (s, 1 H), 6.79-7.55 (m, 7 H, ArH and NHC=SNH), 8.16 (d, $J = 2.2$ Hz, 1 H);

^{13}C NMR (90 MHz CDCl_3) δ 24.65, 26.27, 26.65, 43.94, 44.21, 48.49, 50.87, 106.72, 107.37, 115.34, 126.17, 128.61, 130.56, 130.94, 132.62, 134.68, 139.82, 148.44, 156.29, 181.59.

5

EXAMPLE 26

1-(5-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino) pentyl)-3-(3-(1H-imidazol-4-yl)propyl)thiourea



10

Following the general method as described for N-1-(5-bromopyrid-2-yl)ethane-1,2-diamine, 2,5-dibromopyridine (8.42 g, 35.5 mmol), pyridine (3.54 g, 44.8 mmol), and 15 1,5-diaminopentane (25.0 g, 244.7 mmol) gave an oil. Flash chromatography on silica gel using CH_2Cl_2 50: CH_3OH 50:concentrated NH_4OH 1 as the solvent afforded 5.50 g (60%) of N-1-(5-bromopyrid-2-yl)pentane-1,5-diamine as an oil.

^1H NMR (90 MHz CDCl_3) δ 1.50 (m, 6 H), 1.85 (br s, 2 H, NH_2), 2.72 (m, 2 H), 3.25 (m, 20 2 H), 4.70 (br s, 1 H, NH), 6.30 (d, J = 9 Hz, 1 H, pyridine H-3), 7.47 (dd, 1 H, pyridine H-4), 8.09 (d, 1 H, pyridine H-6);

^{13}C NMR (90 MHz CDCl_3) δ 24.38, 29.40, 33.75, 41.88, 42.50, 106.88, 107.19, 140.00, 149.06, 157.50.

25

In a similar manner as described for the synthesis of N-1-(5-bromopyrid-2-yl)-1-(3,4-dichlorobenzyl) ethane-1,2-diamine, a 60% mineral oil dispersion of sodium hydride (940 mg, 23.4 mmol), N-1-(5-bromopyrid-2-yl)pentane-1,5-diamine (5.50 g, 21.3 mmol), and 3,4-dichlorobenzyl chloride (4.60 g, 23.4 mmol) in DMSO (75 mL)

5 afforded an oil. Purification by flash chromatography on silica gel using CH₂Cl₂ 50: CH₃OH 50: concentrated NH₄OH 1 as the solvent gave 1.46 g (16%) of N-1-(5-bromopyrid-2-yl)-1-(3,4-dichlorobenzyl)pentane-1,5-diamine as an oil.

¹H NMR (90 MHz CDCl₃)d 1.35 (m, 6 H), 2.70 (m, 2 H), 3.40 (t, 2 H), 4.68 (s, 2 H, ArCH₂), 6.35 (d, J = 9 Hz, 1 H, pyridine H-3), 7.35 (m, 4 H, ArH), 8.15 (d, 1 H, pyridine H-6);

¹³C NMR (90 MHz CDCl₃)d 24.38, 27.19, 33.75, 42.20, 49.06, 50.63, 106.25, 107.50, 126.25, 127.81, 130.94, 131.25, 131.90, 139.69, 140.00, 149.06, 156.56.

15

Following the general method, DCC (722 mg, 3.50 mmol), carbon disulfide (2.84 g, 37.3 mmol), and N-1-(5-bromopyrid-2-yl)-1-(3,4-dichlorobenzyl)pentane-1,5-diamine (1.46 g, 3.50 mmol) in THF (45 mL) gave an oil. Flash chromatography using hexane

20 80: EtOAc 20: Et₃N 1 afforded 1.38 g (86%) of 5-[N-(5-bromopyrid-2-yl)-N-(3,4-dichlorobenzyl)]aminopentyl isothiocyanate as an oil.

¹H NMR (90 MHz CDCl₃)d 1.60 (m, 6 H), 3.47 (m, 4 H), 4.69 (s, 2 H, ArCH₂), 6.35 (d, J = 9 Hz, 1 H, pyridine H-3), 7.33 (m, 4 H), 8.17 (d, 1 H, pyridine H-6);

25

¹³C NMR (90 MHz CDCl₃)d 23.99, 26.44, 29.63, 44.86, 48.65, 50.92, 106.72, 107.05, 126.23, 128.72, 130.51, 132.62, 138.90, 139.66, 148.60, 156.24.

30 A solution of 3-[1-(triphenylmethyl)imidazol-4-yl]propylamine (1.02 g, 2.77 mmol) was dissolved in THF (20 mL) and treated dropwise with a solution of 5-[N-(5-bromopyrid-

2-yl)-N-(3,4-dichloro benzyl)]aminopentyl isothiocyanate (1.27 g, 2.77 mmol) in THF (40 mL) at 0-5 °C under a nitrogen atmosphere. The reaction was allowed to warm to room temperature and was stirred overnight. The reaction mixture was treated with additional 3-[1-(triphenylmethyl)imidazol-4-yl]propylamine (0.182 g, 0.495 mmol) and was refluxed for 24 h. Removal of the solvent afforded an oil which was purified by flash chromatography on silica gel using a solvent system of EtOAc 92: CH₃OH 4: Et₃N 4. Fractions homogeneous by TLC were combined and evaporated to yield 2.20 g of a foam. The trityl-protected thiourea was refluxed in 1 N HCl (50 mL) for 1.5 h, and the precipitated triphenylmethanol was removed by filtration. The filtrate was extracted with diethyl ether (2 x 100 mL), washed with water (100 mL), adjusted to pH 14 with 1 N NaOH, and extracted with ethyl acetate (3 x 100 mL). The combined ethyl acetate extracts were washed with water (2 x 50 mL), dried (Na₂SO₄), filtered, and evaporated. The resulting residue was flash chromatographed on silica gel using EtOAc 85: CH₃OH 15:concentrated NH₄OH 1 as the eluent. Fractions homogeneous by TLC were combined and evaporated to yield 500 mg (31%) of the title compound as a foam.


¹H NMR (90 MHz CDCl₃)d 1.15-2.00 (m, 8H), 2.25 (m, 2 H), 3.45 (m, 6 H), 4.64 (s, 2 H, ArCH₂), 6.25-8.13 (m, 10 H, ArH and NHC=SNH);

¹³C NMR (90 MHz CDCl₃)d 23.86, 24.43, 26.98, 29.04, 43.61, 44.64, 48.97, 50.98, 106.78, 107.48, 126.44, 128.88, 130.67, 134.35, 139.17, 139.93, 148.65, 156.51, 181.70.

Anal.

Calcd. for C₂₄H₂₈BrCl₂N₆S: C, 49.32; H, 5.00; N, 14.38.

Found: C, 49.12; H, 5.16; N, 14.15.

EXAMPLE 27

5

N1-[3-(Imidazol-4(5)-yl)propyl]-N2-[3-[(4-bromobenzyl)-N-(pyridin-2-yl)-amino]propyl]-S-methylisothiurea hydroiodide dihydrochloride

- 10 To a solution of N1-[3-(imidazol-4(5)-yl)propyl]-N2-[3-[N-(4-bromobenzyl)-N-(pyridin-2-yl)-amino]propyl]-thiourea dihydrochloride (prepared as in example 1) (580 mg, 1.035 mmol) in absolute ethanol (50 ml) under an atmosphere of nitrogen was added iodomethane (0.10 ml, 1.279 mmol) and the reaction mixture was stirred for 60 h at room temperature. Iodomethane (0.025 ml, 0.32 mmol) was added and the reaction
- 15 mixture stirred at room temperature for an additional 5 h. The volatiles were evaporated in vacuo affording 0.7 g (97%) of the title compound as an amorphous powder.

TLC: R_f = 0.40 (SiO₂; Methanol/Triethylamine = 75:25).

- 20 HPLC retention time = 12.58 minutes (5 μ M C18 4 x 250 mm column, eluting with a gradient of 15% acetonitrile/0.1 N aqueous ammonium sulphate to 25% acetonitrile/0.1 N aqueous ammonium sulphate, pH = 2.5, over 10 minutes at room temperature)

^1H NMR (200 MHz, D_3COD) δ_{H} 2.12 (m, 4H), 2.71 (s, 3H, SCH_3), 2.85 (t, 2H), 3.61 (m, 4H), 3.84 (m, 2H), 4.95 (s, 2H, $\text{CH}_2\text{-Ph}$), 7.02 (t, 1H), 7.22 (d, 2H), 7.30 (d, 1H), 7.42 (bs, 1H), 7.52 (d, 2H), 7.98 (d, 1H), 8.05 (bs, 1H), 8.80 (d, 1H).


CLAIMS

1. Use of a somatostatin receptor ligand of nonpeptide origin, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament, for the treatment of a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal.
2. Use of a somatostatin receptor ligand of nonpeptide origin, or a pharmaceutically acceptable salt thereof, which has high affinity to the somatostatin receptor protein designated SSTR4, for the preparation of a medicament for the treatment of a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal.
3. Use of a somatostatin receptor ligand of nonpeptide origin, or a pharmaceutically acceptable salt thereof, which has high and selective affinity to the somatostatin receptor protein designated SSTR4, for the preparation of a medicament for the treatment of a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal.
4. Use of a somatostatin receptor ligand of nonpeptide origin, or a pharmaceutically acceptable salt thereof, which selectively binds to the somatostatin receptor protein designated SSTR4, for the preparation of a medicament for the treatment of a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal.
5. Use according to any one of claims 1-4 wherein said disease is related to a high intraocular pressure (IOP), such as glaucoma.
6. Use according to any one of claims 1-4 wherein said disease is related to deep ocular infections, such as stromal keratitis, iritis or retinitis.


7. Use according to any one of claims 1-4 wherein said disease is cataract.

8. Use according to any one of claims 1-4 wherein said disease is conjunctivitis.

- 5 9. Use according to any one of the preceding claims wherein said somatostatin receptor ligand of nonpeptide origin has the general formula Ia or Ib



or



wherein

m is 2, 3, 4, 5 or 6,

n is 1, 2 or 3,

- 15 p is 1, 2, 3, 4, 5 or 6,

R¹ and R² are independently hydrogen or C₁₋₆-alkyl optionally substituted with halogen, amino, hydroxy, alkoxy or aryl,


X is =S, =O, =NH, =NCOPh or =N(CN),

- A is aryl optionally substituted with halogen, amino, hydroxy, nitro, C₁₋₆-alkyl, C₁₋₆-alkoxy or aryl,

20 B is aryl optionally substituted with halogen, amino, hydroxy, C₁₋₆-alkyl, C₁₋₆-alkoxy or aryl,

D is aryl, amino, optionally substituted with halogen, amino, hydroxy, C₁₋₆-alkyl, C₁₋₆-alkoxy or aryl,
or a pharmaceutically acceptable salt thereof.

- 5 10. Use according to claim 9 wherein said somatostatin receptor ligand of nonpeptide origin has the general formula Ia



10

wherein

m is 2, 3, 4, 5 or 6,

- 15 n is 1, 2 or 3,

p is 1, 2, 3, 4, 5 or 6,

R¹ and R² are independently hydrogen or C₁₋₆-alkyl optionally substituted with
halogen, amino, hydroxy, alkoxy or aryl,

X is =S, =O, =NH, =NCOPh or =N(CN),

- 20 A is aryl optionally substituted with halogen, amino, hydroxy, nitro, C₁₋₆-alkyl, C₁₋₆-alkoxy or aryl,

B is aryl optionally substituted with halogen, amino, hydroxy, C₁₋₆-alkyl, C₁₋₆-alkoxy
or aryl,

D is aryl, amino, optionally substituted with halogen, amino, hydroxy, C₁₋₆-alkyl,

- 25 C₁₋₆-alkoxy or aryl,

or a pharmaceutically acceptable salt thereof.

11. Use according to claim 9 or 10 wherein X is =S, =NH, =NCOPh, or =N-CN, preferably =S, =NH or =NCOPh.

5 12. Use according to any one of the claims 9-11 wherein A is pyridinyl, quinolinyl, isoquinolinyl, pyrimidinyl, pyrazinyl, pyridazinyl or triazinyl optionally substituted with halogen, amino, hydroxy, nitro, C₁₋₆-alkyl, C₁₋₆-alkoxy or aryl.

10 13. Use according to any one of the claims 9-12 wherein B is phenyl, naphthyl, quinolinyl, isoquinolinyl, indolyl, thienyl, furanyl or pyridinyl optionally substituted with halogen, amino, hydroxy, C₁₋₆-alkyl, C₁₋₆-alkoxy or aryl.

14. Use according to any one of the claims 9-13 wherein D is amino, imidazolyl, pyridinyl, pyrimidinyl, piperidinyl, pyrrolidinyl, piperazinyl, pyridinylamino, pyrimidinylamino, piperidinylamino, pyrrolidinylamino, piperazinylamino, morpholinyl, triazolyl, tetrazolyl, thiadiazolyl, isoxazolyl or oxadiazolyl optionally substituted with halogen, amino, hydroxy, C₁₋₆-alkyl, C₁₋₆-alkoxy or aryl.

15. Use according to any one of the claims 9-14 wherein R₁ and R₂ independently are hydrogen or C₁₋₆-alkyl, preferably hydrogen or methyl.

16. Use according to claim 1-14 or 15 wherein the somatostatin receptor ligand of nonpeptide origin is selected from the group consisting of
N1-[3-(Imidazol-4(5)-yl)propyl]-N2-[3-[N-(4-bromobenzyl)-N-(pyridin-2-yl)-amino]propyl]-S-methylisothiourea, or the hydroiodide, dihydrochloride salt thereof;
1-(3-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl) amino)propyl)-3-(3-(1H-imidazol-4-yl)propyl)thiourea;
1-(3-(N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino)propyl)-3-(3-(1H-imidazol-4-yl)propyl)thiourea, or the dihydrochloride salt thereof;

1-(4-Aminobutyl)-3-(3-(N-(5-bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)propyl)thiourea;

1-(3-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl) amino)propyl)-3-(3-(N-(pyridin-2-yl)amino)propyl)thiourea;

5 1-(3-(N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino)propyl)-3-(3-N,N-dimethylaminopropyl)thiourea;

1-(3-(N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino)propyl)-3-(3-(morpholin-4-yl)propyl)thiourea;

10 1-(3-(N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino)propyl)-3-(3-(imidazol-1-yl)propyl)thiourea, or the dihydrobromide salt thereof;

1-(4-(N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino)butyl)-3-(3-(imidazol-1-yl)propyl)thiourea;

1-(4-(N-(3,4-Dichlorobenzyl)-N-(pyridin-2-yl)amino)butyl)-3-(3-(imidazol-1-yl)propyl)thiourea;

15 1-(3-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)propyl)-3-(3-(imidazol-1-yl)propyl)thiourea;

1-(4-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)butyl)-3-(3-(imidazol-1-yl)propyl)thiourea;

20 1-(3-(N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino)propyl)-3-(4-(N-(pyridin-2-yl)amino)propyl)thiourea;

1-(4-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)butyl)-3-(3-(1H-imidazol-4-yl)propyl)thiourea;

1-(5-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)pentyl)-3-(3-(1H-imidazol-4-yl)propyl)thiourea;

25 1-(4-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)butyl)-3-(2-(1H-imidazol-4-yl)ethyl)thiourea;

1-(2-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)ethyl)-3-(2-(1H-imidazol-4-yl)ethyl)thiourea;

30 1-(2-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)ethyl)-3-(3-(1H-imidazol-4-yl)propyl)thiourea;

1-(3-(N-(5-Bromopyridin-2-yl)-N-((naphth-1-yl)methyl) amino)propyl)-3-(3-(1H-imidazol-4-yl)propyl)thiourea;

1-(4-Aminobutyl)-3-(3-(N-(5-bromopyridin-2-yl)-N-((naphth-1-yl)methyl)amino)propyl)thiourea;

5 1-(3-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)propyl)-3-(2-(pyrid-2-yl)ethyl)thiourea;

1-(3-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)propyl)-3-(3-(pyrrolidin-1-yl)propyl)thiourea;

10 1-(4-Aminobutyl)-3-[3-[N-(5-bromopyrid-2-yl)]-N-(3,4-dichlorobenzyl)]aminopropyl]thiourea;

1-(3-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)propyl)-3-(4-(N-(pyridin-2-yl)amino)propyl)thiourea;

1-(2-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)ethyl)-3-(3-dimethylaminopropyl)thiourea;

15 1-(2-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)ethyl)-3-(3-(pyrrolidin-1-yl)propyl)thiourea;

1-(2-(N-(5-Nitropyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)ethyl)-3-(3-(1H-imidazol-4-yl)propyl)thiourea;

20 1-[3-(((4-Bromobenzyl)pyridin-2-yl)amino)propyl]-3-[2-(1H-imidazol-4-yl)propyl]guanidine;

1-[3-(((4-Bromobenzyl)pyridin-2-yl)amino)propyl]-3-[2-(1H-imidazol-4-yl)ethyl]guanidine;

1-[3-(((4-Bromobenzyl)pyridazin-2-yl)amino)propyl]-3-[3-(1H-imidazol-4-yl)propyl]guanidine;

25 1-[3-(((4-Bromobenzyl)pyridin-3-yl)amino)propyl]-3-[3-(1H-imidazol-4-yl)ethyl]guanidine;

1-[3-[N-(4-Bromobenzyl)-N-(pyrimidin-2-yl)amino]propyl]-3-[3-(1H-imidazol-4-yl)propyl]guanidine;

30 1-[3-[N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino]propyl]-3-[3-(imidazol-1-yl)propyl]guanidine;

1-[3-[N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino]propyl]-3-[3-[N-(pyridin-2-yl)amino]propyl]guanidine;

1-[3-[N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino]propyl]-3-[2-(pyridin-2-yl)ethyl]guanidine;

5 1-[3-[N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino]propyl]-3-[3-(morpholin-4-yl)propyl]guanidine;

1-Methyl-1-[3-(N,N-dimethylamino)propyl]-3-[3-[N-(4-bromobenzyl)-N-(pyridin-2-yl)amino]propyl]guanidine;

1-Benzoyl-2-[3-[(4-bromobenzyl)quinol-2-yl)amino]-propyl]-3-[3-(1*H*-imidazol-4-yl)propyl]guanidine;

10 1-[3-[N-(4-Bromo-benzyl)-N-(quinolin-2-yl)amino]-propyl]-3-[3-(1*H*-imidazol-4-yl)propyl]guanidine, or the trihydrochloride salt thereof; or

1-[3-[N-(4-bromobenzyl)-N-(quinolin-2-yl)amino]propyl]-2-Benzoyl-3-[3-(1*H*-imidazol-4-yl)propyl]guanidine.

15

17. Use according to any one of the claims 1-16 wherein said medicament is formulated for oral, nasal, transdermal, pulmonal or parenteral administration.

18. Use of a compound selected from the group consisting of

20

1-(3-(1*H*-Imidazol-4-yl)propyl)-3-(2-(N-benzyl-N-(3,5-dimethylpyridin-2-yl)ethyl)guanidine;

1-(3-(1*H*-Imidazol-4-yl)propyl)-3-(5-(N-(4-bromobenzyl)-N-(pyridin-2-yl)amino)pentyl)guanidine; or

25 1-(3-(1*H*-Imidazol-4-yl)propyl)-3-(4-(N-(3,4-dichlorobenzyl)-N-(pyridin-2-yl)amino)butyl)guanidine,

or the pharmaceutically acceptable salts thereof,

for the preparation of a medicament for the treatment of a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal.

30

19. Use according to claim 18 wherein said disease is related to a high intraocular pressure (IOP), such as glaucoma.

20. Use according to claim 18 wherein said disease is related to deep ocular infections, such as stromal keratitis, iritis or retinitis.

21. Use according to claim 18 wherein said disease is cataract.

22. Use according to claim 18 wherein said disease is conjunctivitis.

23. A method of treating a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal, comprising administering to said mammal in need thereof an effective amount of a somatostatin receptor ligand of nonpeptide origin or a pharmaceutically acceptable salt thereof.

24. A method of treating a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal, comprising administering to said mammal in need thereof an effective amount of a somatostatin receptor ligand of nonpeptide origin or a pharmaceutically acceptable salt thereof, which has high affinity to the somatostatin receptor protein designated SSTR4.

25. A method of treating a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal, comprising administering to said mammal in need thereof an effective amount of a somatostatin receptor ligand of nonpeptide origin or a pharmaceutically acceptable salt thereof, which has high and selective affinity to the somatostatin receptor protein designated SSTR4.

26. A method of treating a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal, comprising administering to said mammal in need thereof an effective amount of a somatostatin receptor ligand of nonpeptide origin

or a pharmaceutically acceptable salt thereof, which selectively binds to the somatostatin receptor protein designated SSSTR4.

27. The method according to any one of claims 23-26 wherein said disease is related
5 to a high intraocular pressure (IOP), such as glaucoma.


28. The method according to any one of claims 23-26 wherein said disease is related to deep ocular infections, such as stromal keratitis, iritis or retinitis.

10 29. The method according to any one of claims 23-26 wherein said disease is cataract.


30. The method according to any one of claims 23-26 wherein said disease is conjunctivitis.

15

31. The method according to any one of the preceeding method claims wherein said somatostatin receptor ligand of nonpeptide origin has the general formula Ia or Ib



20 or



wherein

m is 2, 3, 4, 5 or 6,

n is 1, 2 or 3,

p is 1, 2, 3, 4, 5 or 6,

R¹ and R² are independently hydrogen or C₁₋₆-alkyl optionally substituted with

5 halogen, amino, hydroxy, alkoxy or aryl,

X is =S, =O, =NH, =NCOPh or =N(CN),

A is aryl optionally substituted with halogen, amino, hydroxy, nitro, C₁₋₆-alkyl, C₁₋₆-alkoxy or aryl,


B is aryl optionally substituted with halogen, amino, hydroxy, C₁₋₆-alkyl, C₁₋₆-alkoxy

10 or aryl,

D is aryl, amino, optionally substituted with halogen, amino, hydroxy, C₁₋₆-alkyl, C₁₋₆-alkoxy or aryl,

or a pharmaceutically acceptable salt thereof.

15 32. The method according to claim 31 wherein said somatostatin receptor ligand of nonpeptide origin has the general formula Ia



20

wherein

m is 2, 3, 4, 5 or 6,

25 n is 1, 2 or 3,

p is 1, 2, 3, 4, 5 or 6,

R¹ and R² are independently hydrogen or C₁₋₆-alkyl optionally substituted with halogen, amino, hydroxy, alkoxy or aryl,

X is =S, =O, =NH, =NCOPh or =N(CN),

A is aryl optionally substituted with halogen, amino, hydroxy, nitro, C₁₋₆-alkyl, C₁₋₆-alkoxy or aryl,

B is aryl optionally substituted with halogen, amino, hydroxy, C₁₋₆-alkyl, C₁₋₆-alkoxy or aryl,

D is aryl, amino, optionally substituted with halogen, amino, hydroxy, C₁₋₆-alkyl, C₁₋₆-alkoxy or aryl,

or a pharmaceutically acceptable salt thereof.

33. The method according to claim 31 or 32 wherein X is =S, =NH, =NCOPh, or =N-CN, preferably =S, =NH or =NCOPh.

34. The method according to any one of the claims 31-33 wherein A is pyridinyl, quinolinyl, isoquinolinyl, pyrimidinyl, pyrazinyl, pyridazinyl or triazinyl optionally substituted with halogen, amino, hydroxy, nitro, C₁₋₆-alkyl, C₁₋₆-alkoxy or aryl.

35. The method according to any one of the claims 31-34 wherein B is phenyl, naphthyl, quinolinyl, isoquinolinyl, indolyl, thienyl, furanyl or pyridinyl optionally substituted with halogen, amino, hydroxy, C₁₋₆-alkyl, C₁₋₆-alkoxy or aryl.

36. The method according to any one of the claims 31-35 wherein D is amino, imidazolyl, pyridinyl, pyrimidinyl, piperidinyl, pyrrolidinyl, piperazinyl, pyridinylamino, pyrimidinylamino, piperidinylamino, pyrrolidinylamino, piperazinylamino, morpholinyl, triazolyl, tetrazolyl, thiadiazolyl, isoxazolyl or oxadiazolyl optionally substituted with halogen, amino, hydroxy, C₁₋₆-alkyl, C₁₋₆-alkoxy or aryl.

37. The method according to any one of the claims 31-36 wherein R₁ and R₂ independently are hydrogen or C₁₋₆-alkyl, preferably hydrogen or methyl.

38. The method according to claim 23-36 or 37 wherein the somatostatin receptor ligand of nonpeptide origin is selected from the group consisting of

N1-[3-(Imidazol-4(5)-yl)propyl]-N2-[3-[N-(4-bromobenzyl)-N-(pyridin-2-yl)-

amino]propyl]-S-methylisothiurea, or the hydroiodide, dihydrochloride salt thereof;

1-(3-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl) amino)propyl)-3-(3-(1H-imidazol-4-yl)propyl)thiourea;

1-(3-(N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino)propyl)-3-(3-(1H-imidazol-4-yl)propyl)thiourea, or the dihydrochloride salt thereof;

1-(4-Aminobutyl)-3-(3-(N-(5-bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)propyl)thiourea;

1-(3-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl) amino)propyl)-3-(3-(N-(pyridin-2-yl)amino)propyl)thiourea;

1-(3-(N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino)propyl)-3-(3-N,N-dimethylaminopropyl)thiourea;

1-(3-(N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino)propyl)-3-(3-(morpholin-4-yl)propyl)thiourea;

1-(3-(N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino)propyl)-3-(3-(imidazol-1-yl)propyl)thiourea, or the dihydrobromide salt thereof;

1-(4-(N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino)butyl)-3-(3-(imidazol-1-yl)propyl)thiourea;

1-(4-(N-(3,4-Dichlorobenzyl)-N-(pyridin-2-yl)amino)butyl)-3-(3-(imidazol-1-yl)propyl)thiourea;

1-(3-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)propyl)-3-(3-(imidazol-1-yl)propyl)thiourea;

1-(4-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)butyl)-3-(3-(imidazol-1-yl)propyl)thiourea;

1-(3-(N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino)propyl)-3-(4-(N-(pyridin-2-yl)amino)propyl)thiourea;

1-(4-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)butyl)-3-(3-(1H-imidazol-4-yl)propyl)thiourea;

1-(5-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)pentyl)-3-(3-(1H-imidazol-4-yl)propyl)thiourea;

1-(4-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)butyl)-3-(2-(1H-imidazol-4-yl)ethyl)thiourea;

5 1-(2-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)ethyl)-3-(2-(1H-imidazol-4-yl)ethyl)thiourea;

1-(2-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)ethyl)-3-(3-(1H-imidazol-4-yl)propyl)thiourea;

10 1-(3-(N-(5-Bromopyridin-2-yl)-N-((naphth-1-yl)methyl) amino)propyl)-3-(3-(1H-imidazol-4-yl)propyl)thiourea;

1-(4-Aminobutyl)-3-(3-(N-(5-bromopyridin-2-yl)-N-((naphth-1-yl)methyl)amino)propyl)thiourea;

1-(3-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)propyl)-3-(2-(pyrid-2-yl)ethyl)thiourea;

15 1-(3-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)propyl)-3-(3-(pyrrolidin-1-yl)propyl)thiourea;

1-(4-Aminobutyl)-3-[3-[N-(5-bromopyrid-2-yl)]-[N-(3,4-dichlorobenzyl)]aminopropyl]thiourea;

20 1-(3-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)propyl)-3-(4-(N-(pyridin-2-yl)amino)propyl)thiourea;

1-(2-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)ethyl)-3-(3-dimethylaminopropyl)thiourea;

1-(2-(N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)ethyl)-3-(3-(pyrrolidin-1-yl)propyl)thiourea;

25 1-(2-(N-(5-Nitropyridin-2-yl)-N-(3,4-dichlorobenzyl)amino)ethyl)-3-(3-(1H-imidazol-4-yl)propyl)thiourea;

1-[3-(((4-Bromobenzyl)pyridin-2-yl)amino)propyl]-3-[2-(1H-imidazol-4-yl)propyl]guanidine;

30 1-[3-(((4-Bromobenzyl)pyridin-2-yl)amino)propyl]-3-[2-(1H-imidazol-4-yl)ethyl]guanidine;

1-[3-(((4-Bromobenzyl)pyridazin-2-yl)amino)propyl]-3-[3-(1H-imidazol-4-yl)propyl]guanidine;

1-[3-(((4-Bromobenzyl)pyridin-3-yl)amino)propyl]-3-[3-(1H-imidazol-4-yl)ethyl]guanidine;

5 1-[3-[N-(4-Bromobenzyl)-N-(pyrimidin-2-yl)amino]propyl]-3-[3-(1H-imidazol-4-yl)propyl]guanidine;

1-[3-[N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino]propyl]-3-[3-(imidazol-1-yl)propyl]guanidine;

10 1-[3-[N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino]propyl]-3-[3-[N-(pyridin-2-yl)amino]propyl]guanidine;

1-[3-[N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino]propyl]-3-[2-(pyridin-2-yl)ethyl]guanidine;

1-[3-[N-(4-Bromobenzyl)-N-(pyridin-2-yl)amino]propyl]-3-[3-(morpholin-4-yl)propyl]guanidine;

15 1-Methyl-1-[3-(N,N-dimethylamino)propyl]-3-[3-[N-(4-bromobenzyl)-N-(pyridin-2-yl)amino]propyl]guanidine;

1-Benzoyl-2-[3-(((4-bromobenzyl)quinol-2-yl)amino)-propyl]-3-[3-(1H-imidazol-4-yl)propyl]guanidine;

20 1-[3-[N-(4-Bromo-benzyl)-N-(quinolin-2-yl)amino]-propyl]-3-[3-(1H-imidazol-4-yl)propyl]guanidine, or the trihydrochloride salt thereof; or

1-[3-[N-(4-bromobenzyl)-N-(quinolin-2-yl)amino]propyl]-2-Benzoyl-3-[3-(1H-imidazol-4-yl)propyl]guanidine.

39. The method according to any one of the claims 23-38 wherein said somatostatin
25 receptor ligand of nonpeptide origin or a pharmaceutically acceptable salt thereof is formulated for oral, nasal, transdermal, pulmonal or parenteral administration.

40. The method according to any one of the claims 23-39, wherein the effective
amount of the somatostatin receptor ligand of nonpeptide origin or a pharmaceutically
30 acceptable salt thereof is in the range of from about 0.0001 to about 100 mg/kg body weight per day, preferably from about 0.001 to about 50 mg/kg body weight per day.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 98/00267

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 31/44, C07D 401/12, C07D 213/74, C07D 413/12
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K, C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CA, WPI

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	WO 9743278 A1 (NOVO NORDISK A/S), 20 November 1997 (20.11.97) --	1-22
P,A	WO 9818786 A1 (NOVO NORDISK A/S), 7 May 1998 (07.05.98) --	1-22
A	Neuroscience Letters, Volume 223, 1997, Mikiro Mori et al, "Differential expression of somatostatin receptors in the rat eye: SSTR4 is intensely expressed in the iris/ciliary body" page 185 - page 188 -- -----	1-22

☐ Further documents are listed in the continuation of Box C.
 ☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

5 October 1998

Date of mailing of the international search report

09 -10- 1998

Name and mailing address of the ISA:
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Eva Johansson
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 98/00267

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 23-40
because they relate to subject matter not required to be searched by this Authority, namely:
See PCT Rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

27/07/98

International application No.
PCT/DK 98/00267

Patent document cited in search report			Publication date	Patent family member(s)			Publication date
WO	9743278	A1	20/11/97	AU	2764797	A	05/12/97
WO	9818786	A1	07/05/98	AU	4772497	A	22/05/98